

Sunil Sharma, MD, FACP, MBA

University of Utah
Huntsman Cancer Institute
2000 Circle of Hope, 3380
Salt Lake City, UT 84112
801-587-5559 (phone)
801-585-0101 (fax)
sunil.sharma@hci.utah.edu

PERSONAL DATA

Citizenship: United States
Languages: English, Hindi

EDUCATION

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
1981 - 1983	AISSC	Sardar Patel Vidyalaya (Biology) New Delhi, India
1983 - 1988	M.D.	University of Delhi (Medicine) New Delhi, India
1988	Intern	University of Delhi Hospital (Rotating Internship) New Delhi, India
1989	Junior Resident	Post Graduate Institute of Medical Education and Research (Radiology) Chandigarh, India
1990 - 1991	Intern	Michael Reese Hospital (Internal Medicine) Chicago, IL
1991 - 1993	Resident	Michael Reese Hospital (Internal Medicine) Chicago, IL
1995 - 1998	Fellow	University of Texas Health Science Center (Medical Oncology) San Antonio, TX
2010 - 2012	M.B.A.	University of Massachusetts (Business Administration) Amherst, MA

BOARD CERTIFICATIONS

01/01/1993 - Present	Federal Licensing Examination, Certified
09/22/1993 - 12/31/2015	American Board of Internal Medicine (Internal Medicine), Expired [Recertified 05/18/2005]
11/19/1997 - 12/31/2017	American Board of Internal Medicine (Sub: Medical Oncology), Diplomate [Recertified 09/04/2007]

LICENSES/CERTIFICATIONS

1990 - Present	Educational Commission for Foreign Medical Graduates
1993 - 1995	State License (AL) - Physician (MD)

1993 - 1996	State License (IL) - Physician (MD)
1993 - 1997	State License (TN) - Physician (MD)
1993 - 1997	State License (GA) - Physician (MD)
1994 - 1996	State License (PA) - Physician (MD)
1995 - 2017	State License (TX) - Physician (MD)
1998 - 2017	State License (NY) - Physician (MD)
2004 - 2017	State License (NV) - Physician (MD)
2008 - 2020	DEA Certificate (UT) - Physician (MD)
2009 - 2018	Controlled Substance (UT) - Physician (MD)
2009 - 2018	State License (UT) - Physician (MD)
2009 - Present	Basic Life Support (UT) - Physician (MD)

CLINICAL AREAS OF SPECIALIZATION

Oncology, Clinical Scientist, Colon Cancer, Liver Cancer, Pancreatic Cancer

RESEARCH INTERESTS

Clinical Trials, Phase I, Gastrointestinal Cancers, Targeted Drug Delivery Systems, Small Molecule Targeted Drug Discovery

PROFESSIONAL EXPERIENCE

Full-Time Positions

1993 - 1995	Physician, Jackson County Rural Health Project, Scottsboro, AL
1998 - 2002	Assistant Attending Physician, Department of Medicine, Division of GI Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
2002 - 2004	Senior Director, Novartis Oncology, Florham Park, NJ
2004 - 2008	Director, Clinical Trials Office, Nevada Cancer Institute, Las Vegas, NV
2004 - 2008	Director of Phase I programs, and Director of Gastrointestinal Oncology, Nevada Cancer Institute, Las Vegas, NV
2004 - 2008	Associate Professor, University of Nevada School of Medicine, Las Vegas, NV
2008 - 2009	Founder, Mantra Bioresearch, Pitampura, Delhi, India
2009 - 2017	Senior Director, Clinical Research, Huntsman Cancer Institute, Salt Lake City, UT
2009 - Present	Investigator, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
2009 - Present	Physician, Huntsman Cancer Institute, Salt Lake City, UT
2009 - Present	Jon and Karen Huntsman Presidential Professorship in Cancer Research Professor of Medicine, University of Utah, Salt Lake City, UT
2009 - Present	Director, Center for Investigational Therapeutics, Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT
2009 - 2012	Adjunct Professor, Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT
2009 - Present	Leader-Experimental Therapeutics Multidisciplinary Group, Huntsman Cancer Institute, Salt Lake City, UT
2010 - Present	Founder, Beta Catenin Pharmaceuticals, Salt Lake City, UT
2010 - Present	Co-Leader, Leader, Experimental Therapeutics Cancer Center Program, Huntsman Cancer Institute, Salt Lake City, UT, Huntsman Cancer Institute, Salt Lake City, UT
2011 - Present	Founder, Salarius Pharmaceuticals, Salt Lake City, UT
2011 - 2015	Board Member, TheraTarget Inc., Salt Lake City, UT
2012 - 2017	Chief, Division of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT
2013 - Present	Adjunct Professor, Department of Pharmaceutics and Pharmaceutical Chemistry,

2015 - 2017 University of Utah, Salt Lake City, UT
 Leader, Experimental Therapeutics Cancer Center Program, Huntsman Cancer Institute, Salt Lake City, UT

2017 - Present Deputy Director, Huntsman Cancer Institute, Salt Lake City, UT

Editorial Experience

1998 - Present Editorial Board for ASCO Online Journal Club

Reviewer Experience

2013 Reviewer for PLOS ONE, Public Library of Science
 Reviewer for Cancer
 Reviewer for Cancer Chemotherapy and Pharmacology
 Reviewer for Cancer Investigation
 Reviewer for Clinical Cancer Research
 Reviewer for Drugs
 Reviewer for European Journal of Cancer
 Reviewer for Expert Opinion on Investigational Drugs
 Reviewer for Investigational New Drugs
 Reviewer for Journal of Clinical Oncology
 Reviewer for Molecular Cancer Therapeutics

SCHOLASTIC HONORS

1983 National Science Talent Scholarship
 1988 Honors in Pathology, Pharmacology, Physiology and Gynecology, University of Delhi
 1998 Pharmacia-Upjohn Award for exemplary research in oncology during fellowship
 2004 Annals of Oncology, Honorable mention for paper of the year
 2007 Fellow of the American College of Physicians

ADMINISTRATIVE EXPERIENCE

Administrative Duties

2009 - Present Director- Center for Investigational Therapeutics, Division of Medical Oncology
 2009 - Present Ad-Hoc Member - Protocol Review and Monitoring Committee (PRMC): performs scientific review of protocols, continued conduct and accrual based goals trials
 2009 - Present Member - HCI Senior Leadership: oversight of the core elements of the CCSG, the Center's research portfolio; provides recommendations to the Executive Director regarding membership; participates in strategic planning for the Center; reviews Program progress; discusses evolution of Shared Resources
 2009 - Present Leader-Experimental Therapeutics Multidisciplinary Group: A weekly treatment planning conference and research in progress meeting to discuss the status of pending Phase I clinical trials, discuss all active, follow-up, and potential Phase I clinical trial patients followed by a clinical, basic, and translational science review and discussion.
 2009 - 2017 Co-Chair-Clinical Research Executive Committee (CREC): oversees clinical research at Huntsman Cancer Institute, including setting policy for the DSMC and PRMC committees and setting priorities for the Clinical Trials Office; reviews general accrual/resource allocations; facilitates integration of research into Huntsman's multidisciplinary clinics; reviews minority recruitment efforts and assists in the development of future plans to enhance patient accrual.
 2010 - 2015 Co-Leader - Experimental Therapeutics Program: developing new therapeutics,

- including image-guided and targeted drug delivery systems; foster bidirectional translation of discoveries between the laboratory and the clinic by developing collaborations and scientific synergy among Cancer Center Program members; advance theoretical and preclinical projects toward human applications in collaborative research projects; develop and execute investigator-initiated imaging, diagnostic, and therapeutic clinical trials to establish new treatments for patients.
- 2010 - Present Leader - Medical Oncology Search Committee: search for the recruitment for 3-4 Associate Professor level physician scientists who can join the Division of Medical Oncology.
- 2012 - Present Member-University of Utah Research Advisory Committee (RAC): advancing areas of strategic priority, including drug discovery
- 2012 - 2017 Chief-Division of Medical Oncology: overall management of the Division of Oncology
- 2015 - Present Co-Leader - Experimental Therapeutics Program: developing new therapeutics, including image-guided and targeted drug delivery systems; foster bidirectional translation of discoveries between the laboratory and the clinic by developing collaborations and scientific synergy among Cancer Center Program members; advance theoretical and preclinical projects toward human applications in collaborative research projects; develop and execute investigator-initiated imaging, diagnostic, and therapeutic clinical trials to establish new treatments for patients.
- 2017 - Present Deputy Director, Huntsman Cancer Institute

Professional Organization & Scientific Activities

- 2009 - Present Committee Member, Southwest Oncology Group, SWOG Gastrointestinal Cancer Committee
- 2011 - Present Panel Member, National Cancer Center Network, NCCN Colon/Rectal/Anal Cancers Panel
- 2016 - Present Committee Member, Oncology Research Information Exchange Network, ORIEN Scientific Committee
- 2016 - Present Committee Member, American Society of Clinical Oncology, ASCO Scientific Program Committee member-Gastrointestinal (Noncolorectal) Cancer track
- 2016 - Present Committee Member, Oncology Research Information Exchange Network, ORIEN Phase I Workgroup
- 2016 - 2017 Invited Speaker, American Association for Cancer Research, AACR Annual Meeting Major Symposia

Grant Review Committee/Study Section

- 2009 - 2010 2010 Pancreatic Cancer Action Network-AACR Innovative Grants Scientific Review Committee
- 2014 NIAID/NIH Special Emphasis Panel/Scientific Review Group - Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01)
- 2015 CCSG Site Visit Review-University of Iowa
- 2016 PAR-16-176: NCI Clinical and Translational Exploratory/Developmental Studies (R21)
Grant Reviewer

PROFESSIONAL COMMUNITY ACTIVITIES

- 2004 - 2008 Consultant, Tragara Pharmaceuticals Inc.
- 2004 - Present Advisory Board Member, Novartis Pharmaceuticals Corporation, Advisory Board

2006 - Present	Consultant, Novartis Pharmaceuticals Corporation, Leading Experts Advising of Development (LEAD) Summit
2008 - Present	Consultant, Novartis Pharmaceuticals Corporation, Annual Business Development and Licensing meeting
2011 - Present	Appointed Committee Member, Vascular Biogenics Limited, Independent Data Monitoring Committee for GT-111001
2015	Advisory Board Member, Guardant Health, Inc., Physician Advisory Board Meeting
2015	Advisory Board Member, Foundation Medicine, Inc., ctDNA Advisory Board
2016	Advisory Board Member, Novartis Pharmaceuticals Corporation, Understanding the Role of Immunotherapy in Oncogenic-driven Lung Cancer
2016	External Advisor, Tisch Cancer Institute, External Advisory Board
2016 - Present	Chair, Array BioPharma Inc., Independent Data Monitoring Committee for ARRAY-818-302

UNIVERSITY COMMUNITY ACTIVITIES

Health Sciences Level

2012 - Present	Committee Member, Health Sciences Center, Health Sciences Research Advisory Committee (RAC)
2015 - 2016	Committee Member, Health Sciences Center, ARUP CEO Search Committee
2016	Committee Member, Health Sciences Center, Clinical Strategy Committee, Cancer Strategy Committee
2016 - Present	Committee Member, Health Sciences Center, Regional Clinical Coordination Council-RC3

Programs, Centers & Institutes

2009 - Present	Ad Hoc Reviewer, Huntsman Cancer Institute, Protocol Review and Monitoring Committee (PRMC) provides scientific review for all cancer trials .
2009 - Present	Council Member, Huntsman Cancer Institute, Research Leadership Council recommends CCSG membership, performs strategic planning, reviews Program progress, reviews the status of Shared Resources, and seeks to improve research and collaboration within the Cancer Center.
2009 - Present	Appointed Member, Huntsman Cancer Institute, Senior Leadership team is responsible for strategic planning, integration, financial management, and evaluation of all three areas of the HCI mission: research, clinical care, and education/outreach.
2009 - Present	Group Leader, Huntsman Cancer Institute, Experimental Therapeutics Multidisciplinary Group (CIT/Phase I): Weekly clinic, treatment planning, and research conference.
2009 - 2017	Co-Chair, Huntsman Cancer Institute, Clinical Research Executive Committee interfaces for clinical affairs and clinical research and responsible for oversight and adjudication for matters involving clinical research; oversees and approves appointments to key committees.
2009 - Present	Member, Huntsman Cancer Institute, Gastrointestinal Cancer Program (GI): identifying new ways to prevent and treat gastrointestinal cancers
2010 - 2015	Co-Leader, Huntsman Cancer Institute, Experimental Therapeutics Program: providing individualized cancer diagnosis and therapy by developing new imaging techniques, diagnostics, and therapeutics.
2010 - Present	Committee Head, Huntsman Cancer Institute, Medical Oncology Search Committee recruiting additional Physician Scientists to become a member of the Division of Medical Oncology.
2015 - Present	Co-Leader, Huntsman Cancer Institute, Experimental Therapeutics Program:

providing individualized cancer diagnosis and therapy by developing new imaging techniques, diagnostics, and therapeutics.
2016 - Present Committee Representative, Huntsman Cancer Institute, HCI Strategic Initiative: Becoming national leaders in therapeutic innovation

SERVICE AT AFFILIATED INSTITUTIONS

2009 - Present Member, Huntsman Cancer Institute/Intermountain Healthcare, Huntsman-Intermountain Cancer Care Program (HICCP): alliance between HCI and IHC to promote excellence in cancer care in Utah.

CONSULTING

2009 Consultant, MedCorp, Inc., consultant 1

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1995 - Present Member, American Society of Clinical Oncology
1996 - Present Member, American Board of Quality Assurance and Utilization Review Physicians, Inc.
1996 - Present Member, Australian Medical Council
1997 - Present Member, American Association for Cancer Research
2000 - Present Member, European Society for Medical Oncology
2007 - Present Fellow, American College of Physicians
2009 - Present Member, NRG Oncology
2009 - Present Member, Southwest Oncology Group
2014 - Present Member, Alliance for Clinical Trials in Oncology
2015 - Present Member, American Chemical Society

FUNDING

Active Grants

10/01/13 - 06/30/17 Epigenetic Regulation of Ewing Sarcoma: A novel approach to influence tumor phenotype and metastasis
Principal Investigator: Mary C. Beckerle
Direct Costs: \$576,000 Total Costs: \$633,640
CureSearch for Children's Cancer
Role: Co Investigator

06/01/14 - 05/31/18 1R01CA183776-01 (PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma
Principal Investigator: Sunil Sharma
Direct Costs: \$1,000,000 Total Costs: \$1,490,000
National Institutes of Health
Role: Co-Principal Investigator

05/01/16 - 04/30/17 5P30CA042014-27 REVISED Experimental Therapeutics Clinical Trials Network (ETCTN) Supplement
Direct Costs: \$33,148 Total Costs: \$49,943
National Institutes of Health
Role: Project Leader

07/11/16 - 07/10/20 Sting Pathway
Principal Investigator: Sunil Sharma
Direct Costs: \$6,591 Total Costs: \$10,000
Stingray Therapeutics LLC

Role: Principal Investigator

Pending Grants

11/28/16 - 11/27/17 Salarius Lsd1 Project
Principal Investigator: Sunil Sharma
Salarius Pharmaceuticals

07/01/17 - 06/30/20 U01 Visualization Cancer Genomics
Principal Investigator: Sunil Sharma
National Institute of Health
Role: Principal Investigator

Past Grants

01/01/01 - 12/31/05 Grant for Breast Cancer Research in the laboratory
Principal Investigator: Sunil Sharma
Direct Costs: \$15,000 Total Costs: \$15,000
Lehman Brothers Foundation
Role: Principal Investigator

06/01/04 - 07/31/06 To study the effect of Histone Deacetylase Inhibitors on Mesothelioma cell lines
Principal Investigator: Sunil Sharma
Direct Costs: \$50,000 Total Costs: \$50,000
Mesothelioma Applied Research Foundation
Role: Principal Investigator

12/01/04 - 12/31/06 Intramural NNCI Grant for Laboratory work on epigenetics
Principal Investigator: Sunil Sharma
Direct Costs: \$50,000 Total Costs: \$50,000
Nevada Cancer Institute
Role: Principal Investigator

01/01/06 - 10/31/08 To study epigenetic effects of azacytidine on cell lines with ovarian and prostate cancers
Principal Investigator: Sunil Sharma
Direct Costs: \$50,000 Total Costs: \$50,000
Pharmion Corporation
Role: Principal Investigator

01/01/07 - 12/31/07 Grant for studying cell death in the laboratory. Development of combination therapies for mesothelioma using cell line models and agents that promote cell death
Principal Investigator: Sunil Sharma
Direct Costs: \$50,000 Total Costs: \$50,000
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

06/01/07 - 10/01/08 Combination of Demethylators and Radiation Therapy in Prostate Cancers
Principal Investigator: Nicholas Vogelzang
Direct Costs: \$450,000 Total Costs: \$450,000
U.S. Department of Defense
Role: Co-Investigator

01/01/12 - 01/15/14 Development Of Kinase Inhibitors
Principal Investigator: Sunil Sharma
Direct Costs: \$82,111 Total Costs: \$122,756
Tolero Pharmaceuticals Inc
Role: Principal Investigator

07/01/12 - 06/30/15 Damon Runyon Clinical Investigator Award "The mitochondrial apoptosis pathway in synovial sarcoma". (\$150,000 for 3 years)
Principal Investigator: Kevin B. Jones
Direct Costs: \$450,000 Total Costs: \$450,000
Damon Runyon Cancer Research Foundation
Role: Mentor

07/19/12 - 06/30/15 1R21CA167795-01
Multi-Tracer PET Assessment of Response to Novel Targeted Chemotherapy
Principal Investigator: John M. Hoffman
Direct Costs: \$207,500 Total Costs: \$207,500
National Cancer Institute
Role: Co Investigator

07/01/13 - 06/30/14 Lessnick Slifka Foundation
Principal Investigator(s): Stephen L. Lessnick; Sunil Sharma
Direct Costs: \$100,000 Total Costs: \$100,000
Alan B. Slifka Foundation
Role: Co-Principal Investigator

10/01/13 - 06/01/15 BTK Inhibitors
Principal Investigator: Sunil Sharma
Direct Costs: \$17,000 Total Costs: \$17,000
University of Utah Technology & Venture Commercialization
Role: Principal Investigator

04/01/14 - 03/31/15 SARC Sarcoma SPORE: Epigenetic Targeting of LSD1 as a Therapeutic Strategy for Ewing Sarcoma
Principal Investigator: Sunil Sharma
Direct Costs: \$40,000 Total Costs: \$50,000
Sarcoma Alliance For Research Through Collaboration
Role: Co-Principal Investigator

08/18/14 - 02/18/15 Lsd1 Inhibitors
Principal Investigator: Sunil Sharma
Direct Costs: \$236,755 Total Costs: \$343,889
Salarius Pharmaceuticals LLC
Role: Principal Investigator

02/17/15 - 11/30/15 HCI-2577 Preclinical Dev.
Principal Investigator(s): Stephen L. Lessnick; Sunil Sharma
Direct Costs: \$150,000 Total Costs: \$150,000
Alan B Slifka Foundation
Role: Co-Principal Investigator

Active Contracts

09/01/10 - 04/06/17 GSK Brf114144 Food Effect Rollover
Principal Investigator: Sunil Sharma
Direct Costs: \$362,652 Total Costs: \$431,330
ICON Clinical Research, Inc.
Role: Principal Investigator

10/18/11 - 07/07/17 Novartis CMEK162x2109
Principal Investigator: Sunil Sharma
Direct Costs: \$366,768 Total Costs: \$438,354
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

11/11/13 - 08/07/18 Gilead Gs-Us-296-0101
Principal Investigator: Sunil Sharma
Direct Costs: \$36,860 Total Costs: \$45,069
Inc Research Inc
Role: Principal Investigator

11/12/13 - 12/31/16 Novartis Lgx818x2103
Principal Investigator: Sunil Sharma
Direct Costs: \$435,815 Total Costs: \$529,169
Novartis
Role: Principal Investigator

01/27/14 - 01/31/19 Novartis Clbh589b2402b
Principal Investigator: Sunil Sharma
Direct Costs: \$12,123 Total Costs: \$15,289
Novartis
Role: Principal Investigator

03/01/14 - 08/31/17 Novartis Cbgj398x2101
Principal Investigator: Sunil Sharma
Direct Costs: \$151,595 Total Costs: \$182,292
Novartis
Role: Principal Investigator

03/13/14 - 02/01/19 Plx120-01 Phase I/Ia
Principal Investigator: Sunil Sharma
Direct Costs: \$205,685 Total Costs: \$264,898
Plexxikon Inc
Role: Principal Investigator

04/10/14 - 10/31/18 Medimmune Medi4736-1108
Principal Investigator: Sunil Sharma
Direct Costs: \$3,427,162 Total Costs: \$4,127,840
Pra International
Role: Principal Investigator

04/14/14 - 08/29/18 Dose Escalation Mgcd265
Principal Investigator: Sunil Sharma
Direct Costs: \$51,352 Total Costs: \$59,133
Methylgene Inc
Role: Principal Investigator

05/01/14 - 06/30/19 IIT Merck Pd-1
Principal Investigator: Sunil Sharma
Direct Costs: \$534,324 Total Costs: \$663,739
HCI / Merck & Company, Inc.
Role: Principal Investigator

07/01/14 - 10/01/19 Incb 24360-204
Principal Investigator: Sunil Sharma
Direct Costs: \$625,366 Total Costs: \$739,701
Parexel Intl
Role: Principal Investigator

07/16/14 - 05/01/19 Onyx Opz009
Principal Investigator: Sunil Sharma
Direct Costs: \$79,324 Total Costs: \$101,588
Onyx Pharmaceuticals Inc
Role: Principal Investigator

10/01/14 - 11/01/19 Xuanzhu 5209-Cpk-1001
Principal Investigator: Sunil Sharma
Direct Costs: \$188,779 Total Costs: \$230,720
Covance Inc
Role: Principal Investigator

11/01/14 - 12/31/18 Sharma Novartis Cbgj398xus04
Principal Investigator: Sunil Sharma
Direct Costs: \$66,114 Total Costs: \$82,842
United Biosource Corporation
Role: Principal Investigator

11/01/14 - 11/01/19 Cc-122-Hcc-001
Principal Investigator: Sunil Sharma
Direct Costs: \$146,241 Total Costs: \$170,223
Celgene Corporation
Role: Principal Investigator

12/01/14 - 02/18/17 Sharma Plexxicon Plx120-03
Principal Investigator: Sunil Sharma
Direct Costs: \$276,363 Total Costs: \$341,457
Synteract Inc
Role: Principal Investigator

02/04/15 - 11/13/18 Novartis Lag525x2101c
Principal Investigator: Sunil Sharma
Direct Costs: \$232,787 Total Costs: \$278,321
Novartis
Role: Principal Investigator

02/13/15 - 10/31/18 Novartis Cpdr001x2101
Principal Investigator: Sunil Sharma
Direct Costs: \$271,701 Total Costs: \$332,722
Novartis
Role: Principal Investigator

03/01/15 - 03/01/20 Blueprint Blu-554-1101
Principal Investigator: Sunil Sharma
Direct Costs: \$179,750 Total Costs: \$222,920
Chiltern
Role: Principal Investigator

07/01/15 - 07/01/20 Fiveprime Fpa008-003
Principal Investigator: Sumati V. Gupta
Direct Costs: \$259,373 Total Costs: \$308,973
Five Prime Therapeutics, Inc.
Role: Sub-Investigator

08/01/15 - 08/01/20 MedImmune D6050c001
Principal Investigator: Sunil Sharma
Direct Costs: \$695,576 Total Costs: \$835,447
Medimmune Inc
Role: Principal Investigator

11/01/15 - 03/05/21 Novartis MIW815
Principal Investigator: Sunil Sharma
Direct Costs: \$341,015 Total Costs: \$417,247
Novartis
Role: Principal Investigator

04/01/16 - 09/05/19 Cpdr001x2102
Direct Costs: \$401,674 Total Costs: \$483,994
Novartis
Role: Sub-Investigator

Pending Contracts

01/01/16 - 01/01/21 Gsk 201893 (9018-0008)
ICON Clinical Research
Role: Sub-Investigator

05/01/16 - 05/01/21 Bms Ca017-003
Principal Investigator: Sunil Sharma
BMS
Role: Principal Investigator

05/01/16 - 05/01/21 Ctmt212x2106
Principal Investigator: Sunil Sharma
Novartis
Role: Principal Investigator

08/01/16 - 08/31/21 CNIZ985x2102j (At-Onc-101)
Principal Investigator: Sunil Sharma
Novartis
Role: Principal Investigator

09/01/16 - 09/01/21 BMS Ca20-002 Tigit
Principal Investigator: Sunil Sharma
BMS
Role: Principal Investigator

12/01/16 - 03/01/22 Phase I/Ib Study Of Nis793
Principal Investigator: Sunil Sharma
Novartis
Role: Principal Investigator

Past Contracts

01/01/04 - 12/31/07 An Open-Label Dose-Escalation Study to Assess the Safety and Bioavailability of Single Oral Doses of Azacitidine in Patients with Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), or Solid Tumors
Principal Investigator: Sunil Sharma
Pharmion Corporation
Role: Principal Investigator

01/01/04 - 12/31/07 Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EGFR inhibitors(s)
Principal Investigator: Sunil Sharma
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

01/01/04 - 12/31/07 A Phase II Clinical Trial of Oral Valproic Acid (VPA) in Patients with Castration Resistant Prostate Cancers
Principal Investigator: Sunil Sharma
Nevada Cancer Institute
Role: Principal Investigator

01/01/04 - 12/31/07 A Phase I/II , multi-center, randomized dose escalation of oral AEE788 on intermittent dosing schedules in adult patients with advanced cancer
Principal Investigator: Sunil Sharma

Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 01/01/04 - 12/31/07 A Two-cohort Phase I Trial of PTK787 and Pemetrexed with or without Cisplatin in Patients with advanced solid tumors
 Principal Investigator: Sunil Sharma
 Nevada Cancer Institute
 Role: Principal Investigator
 01/01/04 - 12/31/07 A Clinical Trial of Chemotherapy & Bevacizumab With or Without Panitumumab in 1st Line Treatment of Subjects with Metastatic Colorectal Cancer
 Principal Investigator: Sunil Sharma
 Amgen Inc.
 Role: Principal Investigator
 01/01/04 - 12/31/07 Effect of Esomeprazole on the Pharmacokinetics of BMS-275183 in Patients with Advanced Malignancies A Phase I/II , multi-center, randomized dose escalation of oral AEE788 on intermittent dosing schedules in adult patients with advanced cancer
 Principal Investigator: Sunil Sharma
 Bristol-Myers Squibb
 Role: Principal Investigator
 01/01/04 - 12/31/08 A Phase I/II, multi-center, open label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patient with advanced solid malignancies including patients with advanced breast cancer
 Principal Investigator: Sunil Sharma
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 01/01/04 - 12/31/08 A Phase IA, two-arm, multicenter, dose-escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors and non-Hodgkin's lymphoma
 Principal Investigator: Sunil Sharma
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 01/01/04 - 12/31/08 A Phase I trial of BEZ235 (a PI3 Kinase inhibitor) in solid tumors
 Principal Investigator: Sunil Sharma
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 01/01/04 - 12/31/08 A Continuation Clinical Trial of Oral L-001079038 in Advanced Cancers (Completed accrual)
 Principal Investigator: Sunil Sharma
 Merck & Co., Inc.
 Role: Principal Investigator
 01/01/04 - 12/31/08 A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid In Combination with Pemetrexed & Cisplatin In Patients with Advanced Cancer (Completed accrual)
 Principal Investigator: Sunil Sharma
 Merck & Co., Inc.
 Role: Principal Investigator
 01/01/04 - 12/31/08 A Phase II, Open, Randomized Study To Assess The Efficacy of AZD6244 vs Capecitabine (Xelolda) In Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy (Gemzar)
 Principal Investigator: Sunil Sharma

AstraZeneca
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I trial of Cisplatin combined with CBP501 (a G2/M blocker) in advanced solid tumors
Principal Investigator: Sunil Sharma
CanBas Co., Ltd.
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I Trial of BGT226 in patients with advanced solid tumors
Principal Investigator: Sunil Sharma
Novartis Pharmaceuticals Corporation
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I/ II Trial of Cisplatin, Pemetrexed and CBP501 in patients with advanced solid tumors and mesotheliomas
Principal Investigator: Sunil Sharma
CanBas Co., Ltd.
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I trial of oral picoplatin in advanced solid tumors
Principal Investigator: Sunil Sharma
Poniard Pharmaceuticals
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
Principal Investigator: Sunil Sharma
Eisai, Inc.
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I trial of LBH589 in combination with ketoconazole in patients with advanced solid tumors
Principal Investigator: Sunil Sharma
Novartis Pharmaceuticals Corporation
Role: Principal Investigator
01/01/04 - 12/31/08 A phase I trial of AUY922 (a heat shock protein inhibitor) in solid tumors
Principal Investigator: Sunil Sharma
Novartis Pharmaceuticals Corporation
Role: Principal Investigator
01/01/04 - 12/31/08 A Randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combinations with chemotherapy and bevacizumab in patients with metastatic colorectal cancer preceded by a phase I portion
Principal Investigator: Sunil Sharma
Pfizer, Inc.
Role: Principal Investigator
01/01/04 - 12/31/08 Multiple Ascending Dose (MAD) Phase I Study of RO4612910 Administered Orally on a Daily x 14 Consecutive Days every 3 Week Schedule in Patients with A Phase I Study of RO4612910 Administered Orally QD x Days Q 3 Wks Schedule In Pts With Adv Solid Tumors
Principal Investigator: Sunil Sharma
F. Hoffmann-La Roche Ltd
Role: Principal Investigator
01/01/04 - 12/31/08 An open-label, multi-center, 2-arm Phase I/II trial of LBY135 alone and in combination with capecitabine in advanced solid tumors
Principal Investigator: Sunil Sharma

Novartis Pharmaceuticals Corporation
Role: Principal Investigator
01/01/04 - 12/31/08 A Phase I study of EC-0225 in treatment of solid tumors
Principal Investigator: Sunil Sharma
Endocyte
Role: Principal Investigator
04/15/09 - 02/29/12 Kras Decitabine & Panitumumab
Principal Investigator(s): Kimberly A. Jones; Sunil Sharma
Direct Costs: \$294,640 Total Costs: \$323,029
Amgen Inc
Role: Principal Investigator
07/15/09 - 12/31/11 Canbas Cbp08-01 (Mesothelioma)
Principal Investigator: Sunil Sharma
AAIPharma, Inc.
Role: Principal Investigator
07/15/09 - 12/31/11 Acceleron A041-01
Principal Investigator: Sunil Sharma
Acceleron Pharma, Inc.
Role: Principal Investigator
08/01/09 - 04/30/11 Mebiopharma Mbp-426 201
Principal Investigator: Sunil Sharma
AAIPharma, Inc.
Role: Principal Investigator
09/01/09 - 12/31/12 Celgene Amrubicin
Principal Investigator: Sunil Sharma
PRA International
Role: Principal Investigator
10/01/09 - 06/30/14 Millennium C14007
Principal Investigator: Sunil Sharma
Direct Costs: \$340,758 Total Costs: \$432,665
Millennium Pharmaceuticals, Inc.
Role: Principal Investigator
12/01/09 - 04/30/13 Novartis Clbh589x2105 (Renal)
Principal Investigator: Sunil Sharma
Direct Costs: \$190,825 Total Costs: \$237,000
Novartis Pharmaceuticals Corporation
Role: Principal Investigator
12/01/09 - 04/30/13 Novartis Clbh589x2101(Hepatic)
Principal Investigator: Sunil Sharma
Direct Costs: \$175,705 Total Costs: \$219,000
Novartis Pharmaceuticals Corporation
Role: Principal Investigator
01/01/10 - 12/31/12 Merrimack Mm-111-01-102 Breast
Principal Investigator: Sunil Sharma
Direct Costs: \$316,021 Total Costs: \$375,112
INC Research, Inc.
Role: Principal Investigator
01/21/10 - 01/30/12 Novartis Ctki258a2112
Principal Investigator: Sunil Sharma
Direct Costs: \$517,721 Total Costs: \$650,986

Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 02/01/10 - 04/30/13 Qt-Cab: Tes10884
 Principal Investigator: Sunil Sharma
 Sanofi-Aventis
 Role: Principal Investigator
 03/01/10 - 06/30/13 Millennium Tak-960
 Principal Investigator: Sunil Sharma
 Direct Costs: \$511,664 Total Costs: \$619,637
 Millennium Pharmaceuticals, Inc.
 Role: Principal Investigator
 03/01/10 - 03/05/14 IIT/Novartis Rad001
 Principal Investigator: Sunil Sharma
 Direct Costs: \$223,729 Total Costs: \$287,000
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 04/15/10 - 06/09/13 Novartis Ctki258a2116
 Principal Investigator: Sunil Sharma
 Direct Costs: \$551,743 Total Costs: \$686,455
 Novartis Pharmaceuticals Corporation
 Role: Principal Investigator
 05/01/10 - 12/31/12 IIT/Jubilant Ji-101/Everolimus Clinical Trial
 Principal Investigator(s): Neeraj Agarwal; Sunil Sharma
 Direct Costs: \$339,697 Total Costs: \$436,000
 Jubilant Innovation Ltd
 Role: Principal Investigator
 05/01/10 - 12/31/12 Jubilant JI-101 collaborative
 Principal Investigator: Sunil Sharma
 Direct Costs: \$126,000 Total Costs: \$126,000
 Jubilant Innovation Ltd
 Role: Principal Investigator
 05/01/10 - 04/22/13 J&J Et743-Ovc-1002
 Principal Investigator: Sunil Sharma
 Direct Costs: \$132,830 Total Costs: \$158,642
 ReSearch Pharmaceutical Services, Inc.
 Role: Principal Investigator
 07/27/10 - 07/27/11 Jubilant Ji-101 Research Project
 Principal Investigator: Sunil Sharma
 Jubilant Innovation Ltd
 Role: Principal Investigator
 08/01/10 - 06/30/12 GSK BRF113468 Zm2010/00004/00 (Food Effect)
 Principal Investigator: Sunil Sharma
 ICON Clinical Research, Inc.
 Role: Principal Investigator
 08/01/10 - 12/31/14 Cln20: Belinostat And Warfarin
 Principal Investigator: Sunil Sharma
 Direct Costs: \$270,257 Total Costs: \$312,610
 Spectrum Pharmaceuticals, Inc.
 Role: Principal Investigator
 10/13/10 - 07/08/17 Novartis CLDK378x2101

Principal Investigator(s): Wallace L. Akerley; Kimberly Jones; Sunil Sharma;
Theresa L. Werner
Direct Costs: \$323,705 Total Costs: \$393,066
Novartis Pharmaceuticals Corporation
Role: Co-Principal Investigator

01/01/11 - 04/10/13 Eli Lilly I4t-Mc-JVBT
Principal Investigator: Sunil Sharma
Direct Costs: \$225,921 Total Costs: \$266,516
Eli Lilly and Company
Role: Principal Investigator

03/01/11 - 07/31/13 Brf113771 (Gsk2118436)
Principal Investigator: Sunil Sharma
Direct Costs: \$139,907 Total Costs: \$170,139
ICON Clinical Research, Inc.
Role: Principal Investigator

03/01/11 - 11/25/13 CMEK162x2102 (Mek 162+Raf265)
Principal Investigator: Sunil Sharma
Direct Costs: \$430,732 Total Costs: \$515,788
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

03/01/11 - 04/17/14 GSK Egf114271 Lapatinib
Principal Investigator: Sunil Sharma
Direct Costs: \$115,754 Total Costs: \$140,941
PRA International
Role: Principal Investigator

03/01/11 - 04/17/14 GSK Egf111767 Lapatinib Rollover
Principal Investigator: Sunil Sharma
Direct Costs: \$41,646 Total Costs: \$53,510
PRA International
Role: Principal Investigator

07/01/11 - 03/31/14 MM-121-05-01-05
Principal Investigator: Sunil Sharma
Direct Costs: \$328,479 Total Costs: \$386,168
INC Research, Inc.
Role: Principal Investigator

08/01/11 - 11/05/14 Millenium C16009
Principal Investigator: Sunil Sharma
Direct Costs: \$194,568 Total Costs: \$243,677
ICON Clinical Research, Inc.
Role: Principal Investigator

08/12/11 - 08/11/13 Beta Cat
Principal Investigator: Sunil Sharma
Direct Costs: \$21,739 Total Costs: \$25,000
Beta Cat Pharmaceuticals, LLC
Role: Principal Investigator

09/01/11 - 01/31/14 Novartis CLDE225x2103
Principal Investigator: Sunil Sharma
Direct Costs: \$143,583 Total Costs: \$175,356
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

09/05/11 - 06/17/13 Novartis CTKI258a2128
Principal Investigator: Sunil Sharma
Direct Costs: \$182,155 Total Costs: \$222,232
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

01/01/12 - 05/15/14 GSK 2636771 P3B115717
Principal Investigator: Sunil Sharma
Direct Costs: \$381,529 Total Costs: \$481,880
GlaxoSmithKline
Role: Principal Investigator

01/01/12 - 06/30/14 Amg 386
Principal Investigator: Sunil Sharma
Direct Costs: \$389,095 Total Costs: \$461,395
Amgen Inc.
Role: Principal Investigator

01/01/12 - 01/01/17 Correlative Tissue Bk-Ls-Am101
Principal Investigator: Sunil Sharma
Direct Costs: \$170,727 Total Costs: \$226,555
Lsk Biopartners
Role: Principal Investigator

02/01/12 - 11/30/14 Cmek162x2111
Principal Investigator: Sunil Sharma
Direct Costs: \$329,900 Total Costs: \$398,305
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

06/01/12 - 04/30/15 Novartis LDE2114 LDE225 & BKM120
Principal Investigator: Sunil Sharma
Direct Costs: \$114,798 Total Costs: \$142,566
Novartis Pharmaceuticals Corporation
Role: Principal Investigator

07/13/12 - 07/12/14 Tolero Pharmaceuticals Project
Principal Investigator: Sunil Sharma
Direct Costs: \$123,936 Total Costs: \$123,936
Tolero Pharmaceuticals, Inc.
Role: Principal Investigator

12/10/12 - 12/31/15 Novartis Lde225a2112
Principal Investigator: Sunil Sharma
Direct Costs: \$247,846 Total Costs: \$312,026
Novartis
Role: Principal Investigator

02/01/13 - 06/30/16 Ldk378x2102
Principal Investigator: Sunil Sharma
Direct Costs: \$613,387 Total Costs: \$782,004
Novartis
Role: Principal Investigator

04/11/13 - 04/10/16 GSK MEK114655
Principal Investigator: Sunil Sharma
Direct Costs: \$63,826 Total Costs: \$63,826
GlaxoSmithKline
Role: Principal Investigator

04/11/13 - 04/10/17 GSK MEK114375 rollover
Principal Investigator: Sunil Sharma
Direct Costs: \$32,327 Total Costs: \$32,327
GlaxoSmithKline
Role: Principal Investigator

07/31/13 - 06/30/16 Novartis Ldk378a2402
Principal Investigator: Sunil Sharma
Direct Costs: \$40,730 Total Costs: \$50,993
Novartis
Role: Principal Investigator

12/02/13 - 04/01/14 Et743-Ovc-1004
Principal Investigator: Sunil Sharma
Direct Costs: \$37,790 Total Costs: \$44,778
Johnson & Johnson
Role: Principal Investigator

03/14/14 - 03/13/17 IIT Regorafenib + Panit
Principal Investigator: Sunil Sharma
Direct Costs: \$223,346 Total Costs: \$294,558
HCI / Bayer
Role: Principal Investigator

04/01/14 - 03/01/17 Novartis Cinc280x2104
Principal Investigator: Sunil Sharma
Direct Costs: \$131,804 Total Costs: \$169,247
Novartis
Role: Principal Investigator

05/01/14 - 09/01/19 Ignyta Rxdx-101-01
Principal Investigator: Sunil Sharma
Direct Costs: \$114,934 Total Costs: \$143,522
Ignyta Operating, Inc.
Role: Principal Investigator

Independent Research

2008 - 2009 Founder, Mantra Bioresearch
Pitampura, Delhi

2010 - Present Founder, Beta Catenin Pharmaceuticals
Salt Lake City, UT

2011 - Present Founder, Salarius Pharmaceuticals
Salt Lake City, UT

TEACHING RESPONSIBILITIES/ASSIGNMENTS

Course Lectures

2013 Primary Instructor, PHCEU 7970 (24): Thesis Research-PhD, 9 SCH, 1 student,
University of Utah, Pharmaceutics and Pharmaceutical Chemistry

2014 Primary Instructor, PHCEU 7970 (24): Thesis Research-PhD, 9 SCH, 1 student,
University of Utah, Pharmaceutics and Pharmaceutical Chemistry

2014 Primary Instructor, PHCEU 7970 (25): Thesis Research-PhD, 3 SCH, 1 student,
University of Utah, Pharmaceutics and Pharmaceutical Chemistry

Clinical Teaching

2010 - Present Weekly research and continuity fellow
Huntsman Cancer Institute Clinic

2011 - Present Attending with 4-5 residents
Huntsman Cancer Hospital

Trainee Supervision

Fellow

2010 - 2011 Advisor/Mentor, G. Weldon Gilcrease, MD, University of Utah. Hem/Onc Fellowship - Clinical Teaching and Laboratory Teaching
Trainee's Current Career Activities: University of Utah, Huntsman Cancer Institute Oncologist/Investigator

2010 - 2011 Advisor/Mentor, Luke Huerter, MD, University of Utah. Hem/Onc Fellowship - Clinical Teaching
Trainee's Current Career Activities: Oncologist - Lawrence Memorial Hospital

2011 - 2013 Advisor/Mentor, Aaron Luebke, MD, University of Utah. Hem/Onc Fellowship - Clinical Teaching and Laboratory Teaching
Trainee's Current Career Activities: Oncologist - Mid Dakota Clinic

2012 - 2013 Advisor/Mentor, Jesal Patel, MD, University of Utah. Hem/Onc Fellowship - Clinical Teaching and Laboratory Teaching
Trainee's Current Career Activities: Oncologist - Arizona Oncology

2012 - 2014 Advisor/Mentor, Qing Zhao, MD, University of Utah. Hem Onc Fellow - Clinical Teaching and Laboratory Teaching

2012 - 2014 Advisor/Mentor, Sumati Gupta, MD, University of Utah. Hem Onc Fellow - Clinical Teaching and Laboratory Teaching

2013 - 2015 Advisor/Mentor, Zachary Reese, MD, University of Utah. Hem/Onc Fellowship - Clinical Teaching and Laboratory Teaching
Trainee's Current Career Activities: University of Utah, Huntsman Cancer Institute Oncologist/Investigator

2014 Advisor/Mentor, Conan Kinsey, University of Utah. Hem Onc Fellow - Clinical Teaching and Laboratory Teaching

2015 - Present Advisor/Mentor, Allison Ast, University of Utah. Laboratory Teaching
Trainee's Current Career Activities: Pediatric Oncology Fellow

2016 Advisor/Mentor, Austin Poole, University of Utah. Hem Onc Fellow - Clinical Teaching

2016 Advisor/Mentor, Clarke Low, University of Utah. Hem Onc Fellow - Clinical Teaching

Undergraduate

2016 Advisor/Mentor, Kapil Sharma, University of Utah. Advisor for Kapil Sharma on his Spring 2016 Honors thesis

Graduate Student Committees

2011 - 2013 Member, Brandon Buckway, PhD, University of Utah, PhD/Doctorate Committee. Ph.D. Graduate Student, Department of Pharmaceutics and Pharmaceutical Chemistry, Supervisory Committee

2011 - 2013 Member, Nate Larson, PhD, University of Utah, PhD/Doctorate Committee. Ph.D. Graduate Student, Department of Pharmaceutics and Pharmaceutical Chemistry, Supervisory Committee

2012 - 2014 Chair, Emily Theisen, PhD, University of Utah, PhD/Doctorate Committee. PhD Candidate-Department of Pharmaceutics and Pharmaceutical Chemistry

2013 - 2016 Member, Nicholas Frazier, University of Utah, PhD/Doctorate Committee. Ph.D. Graduate Student, Department of Bioengineering Supervisory Committee

2013 - 2015 Member, Jason Tanner, University of Utah, PhD/Doctorate Committee. Department of Oncological Sciences

Educational Lectures

Department/Division Conferences

2009 - Present	Experimental Therapeutics (Phase I) Research in Progress Huntsman Cancer Institute Physician, Mid-level, Fellow, RN, Staff
2011	Biology of Cancer, Part 1 Hematology/Oncology Fellows Conference Huntsman Cancer Institute
2012	Upper GI Malignancies Hematology/Oncology Fellows Conference Huntsman Cancer Institute
2012	Targeting beta catenin by disrupting protein-protein interaction Hematology/Oncology Fellows Conference Huntsman Cancer Institute
2012	Biology of Cancer, Part 4: Carcinogenesis Hematology/Oncology Fellows Conference Huntsman Cancer Institute
2012	Upper GI Cancers Hematology/Oncology Fellows Conference Huntsman Cancer Institute
2013	Targeting Wnt Pathway in Cancer Hematology/Oncology Fellows Conference Huntsman Cancer Institute
2015	Upper GI Cancers Hematology/Oncology Fellows Conference Huntsman Cancer Institute

PEER-REVIEWED JOURNAL ARTICLES

1. **Sharma S**, Marini D (1996). Acute Myocardial Infarction in a patient with Chronic Myelogenous Leukemia. *Ann Hematol*, 72, 153-154.
2. **Sharma S**, Weiss GA, Paulger B (1997). Pityriasis Rubra Pilaris as a presenting feature of Hepatocellular Carcinoma. *Dermatology*, 194, 166-167.
3. **Sharma S**, Raymond E, Soda H, Von Hoff DD (1997). Telomerase inhibitors in pre-clinical development. *Expert Opin Investig Drugs*, 6, 1179-1185.
4. **Sharma S**, Diab S (1997). Commentary on broadening office skills for Oncologists. (Current Clinical Practice Section). *Semin Oncol*, 24, xxxi-xxxv.
5. **Sharma S**, Vukelja S, Kadakia S (1997). Gilbert's syndrome coexisting and masking Hereditary Spherocytosis. *Ann Hematol*, 74, 287-289.
6. **Sharma S**, Raymond E, Soda H, Sun D, Hilsenbeck S.G., Sharma A, Izbicka E, Windle B, Von Hoff DD (1997). Preclinical and clinical strategies for development of telomerase and telomere inhibitors. *Ann Oncol*, 8, 1063-1067.
7. Soda H, Raymond E, **Sharma S**, Lawrence R, Cerna C, Gomez L, Timony GA, Von Hoff DD, Izbicka E (1998). Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. *Anticancer Drugs*, 9, 327-331.
8. Raymond E, **Sharma S**, Sun D, Champlin RE, Soda H, Boldt DH, Von Hoff DD (1998). Sensitivity and specificity of telomerase to detect cancer cells in routine human biopsies. *Ann Oncol*, 9S2, 183.
9. Raymond E, Izbicka E, Sun D, **Sharma S**, Soda H, Mangold G, Silvas E, Windle B, Laurence R, Davidson K, Von Hoff D (1998). In vitro telomerase inhibitors in human cancer cell models using a biotinylated-primer extension assay. *Ann Oncol*, 9S2, 140.

10. **Sharma S**, Raymond E, Soda, H, Izbicka, E, Davidson, K, Lawrence, R, Von Hoff, DD (1998). Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line. *Leuk Res*, 22, 663-670.
11. Raymond E, Sun D, Izbicka E, Mangold G, Silvas E, Windle B, **Sharma S**, Soda H, Laurence R, Davidson K, Von Hoff DD (1999). A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay. *Br J Cancer*, 80, 1332-41.
12. **Sharma S** (1999). Novel mathematical approaches for understanding gene expression data and its role in anticancer drug development and target selection. *Clin Cancer Res*, 5, 3844s.
13. Soda H, Raymond E, **Sharma S**, Lawrence R, Cerna C, Gomez L, Schaub R, Von Hoff DD, Izbicka E (1999). Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors. *Anticancer Drugs*, 10, 97-101.
14. O'Reilly E, Hammond L, Donehower R, Schwartz G, Kelvin J, Aird S, **Sharma S**, Schrag D, Molloy K, DeJager R (2000). A phase II study of exatecan mesylate (DX-8951f) in advanced pancreatic cancer. *Ann Oncol*, 11(Suppl. 4), 63.
15. Soda H, Raymond E, **Sharma S**, Lawrence R, Davidson K, Oka M, Kohno S, Izbicka E, Von Hoff DD (2000). Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro. *Prostate*, 15(43(3)), 161-8.
16. **Sharma S**, Saltz LB (2000). Oral chemotherapeutic agents for colorectal cancer. *Oncologist*, 5(2), 99-107.
17. **Sharma S**, Gonen M (2000). Fluoropyrimidine chemotherapy improves 1-year mortality in people with stage IV or unresectable colorectal cancer compared with supportive care. *Evidence - Based Oncology*, 1, 116.
18. Culliford AT, Brooks AD, **Sharma S**, Saltz LB, Schwartz GK, O'Reilly EM, Ilson DH, Kemeny NE, Kelsen DP, Guillem JG, Wong WD, Cohen AM, Paty PB (2001). Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. *Ann Surg Oncol*, 8, 787-795.
19. **Sharma S**, Kemeny N, Schwartz GK, Kelsen D, O'Reilly E, Ilson D, Coyle J, DeJager R, Ducharme M, Kleban S, Hollywood E, Saltz LB (2001). A phase I study of topoisomerase I inhibitor Exatecan Mesylate (DX-8951f) given as weekly 24-hour infusions every three of four weeks. *Clin Cancer Res*, 7(12), 3963-70.
20. **Sharma S**, White D, Imondi AR, Placke ME, Vail DM, Kris MG (2001). Development of inhalational agents for oncologic use. *J Clin Oncol*, 19(6), 1839-1847.
21. **Sharma S**, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB (2002). A Phase II Trial of farnesyl protein transferase inhibitor SCH 66336 given by Twice-Daily Oral Administration in Patients With Metastatic Colorectal Cancer Refractory to Fluorouracil and Irinotecan. *Ann Oncol*, 13, 1067-1071.
22. Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, **Sharma S**, Garham MA (2002). Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. *Ann Oncol*, 13, 1490-1496.
23. Schwartz GK, O'Reilly E, Ilson D, Saltz L, **Sharma S**, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D (2002). Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. *J Clin Oncol*, 20(8), 2157-70.
24. Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K, Koblan KS, Lee Y, Mosser S, Motzel SL, Abbruzzese JL, Fuchs CS, Rowinsky EK, Rubin EH, **Sharma S**, Deutsch PJ, Mazina KE, Morrison BW, Wildonger L, Yao SL, Kohl NE (2002). Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. *Mol Cancer Ther*, 1(9), 747-58.
25. Nash GM, Saltz LB, Kemeny NE, Minsky B, **Sharma S**, Schwartz GK, Ilson DH, O'Reilly E, Kelsen DP, Nathanson DR, Weiser M, Guillem JG, Wong WD, Cohen AM, Paty PB (2002).

- Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. *Ann Surg Oncol*, 9(10), 954-60.
26. Takimoto CH, Remick SC, **Sharma S**, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL (2003). Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. *J Clin Oncol*, 21(14), 2664-72.
 27. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, **Sharma S**, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P (2003). Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. *Semin Oncol*, 30(4 Suppl 15), 14-9.
 28. Takimoto CH, Remick SC, **Sharma S**, Mani S, Ramanathan RK, Doroshow JH, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Greenslade D, Goetz A, Grem JL (2003). Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. *Semin Oncol*, 30(4 Suppl 15), 20-5.
 29. Abou-Alfa GK, Rowinsky EK, Patt YZ, Schwartz GK, Kelsen DP, **Sharma S**, Siegel E, Becerra CR, Eckhardt SG, Feit K, De Jager R, O'Reilly EM (2005). A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. *Am J Clin Oncol*, 28(4), 334-9.
 30. Fury MG, Krug LM, Azzoli CG, **Sharma S**, Kemeny N, Wu N, Kris MG, Rizvi NA (2006). A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. *Cancer Chemother Pharmacol*, 57(5), 671-7.
 31. Lee L, **Sharma S**, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM (2006). Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. *Cancer Chemother Pharmacol*, 57(6), 761-71.
 32. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, **Sharma S**, Kantarjian H, Dugan M, Albitar M, Bhalla K (2006). A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. *Clin Cancer Res*, 12(15), 4628-35.
 33. Otterson GA, Villalona-Calero MA, **Sharma S**, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, Murren JR (2007). Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. *Clin Cancer Res*, 13(4), 1246-52.
 34. Coates SS, Lehnert BE, **Sharma S**, Kindell SM, Gary RK (2007). Beryllium induces premature senescence in human fibroblasts. *J Pharmacol Exp Ther*, 322(1), 70-9.
 35. Garcia-Manero G, Stoltz M, Ward R, Kantarjian H, **Sharma S** (2008). A Pilot Pharmacokinetic Study of Oral Azacitidine. *Leukemia*, 22(9), 1680-4.
 36. **Sharma S**, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N (2008). A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. *Transl Oncol*, 1(3), 141-7.
 37. **Sharma S**, Freeman B, Turner J, Symanowski J, Manno P, Berg W, Vogelzang N (2009). A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors. *Invest New Drugs*, 27, 63-65.
 38. Symanowski J, Vogelzang N, Atadja P, Zawel L, Pass H, **Sharma S** (2009). A histone deacetylase inhibitor LBH589 downregulates X-linked inhibitor of apoptosis (XIAP) in mesothelioma cell lines which is likely responsible for increased apoptosis in combination with tumor necrosis factor alpha related apoptosis inducing ligand (TRAIL). *J Thorac Oncol*, 4(2), 149-60.
 39. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, **Sharma S**, Gross

- SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. *Ann Oncol*, 20(10), 1674-81.
40. **Sharma S**, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL (2010). A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. *Ann Oncol*, 21(2), 297-304.
 41. Gouw LG, Jones KB, **Sharma S**, Randall RL (2011). Sarcoma immunotherapy. *Cancers (Basel)*, 3(4), 4139-50.
 42. Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff D, Kawabe T, **Sharma S** (2011). Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. *Clin Cancer Res*, 17(10), 3431-42.
 43. Jones KB, Haldar M, Schiffman JD, Cannon-Albright L, Lessnick SL, **Sharma S**, Capecchi MR, Randall RL (2011). Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation. *Cancer Control*, 18(3), 196-203.
 44. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, **Sharma S**, Hengelage T, de Jonge M (2011). Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. *Cancer Chemother Pharmacol*, 68(3), 805-13.
 45. Verma A, Warner SL, Vankayalapati H, Bearss DJ, **Sharma S** (2011). Targeting Axl and Mer kinases in cancer. *Mol Cancer Ther*, 10(10), 1763-73.
 46. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW Jr, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C (2011). Colon cancer. *J Natl Compr Canc Netw*, 9(11), 1238-90.
 47. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, **Sharma S**, Vankayalapati H, Bearss DJ (2011). Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. *ACS Med Chem Lett*, 2(12), 907-912.
 48. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA (2012). Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw*, 10(4), 449-54.
 49. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM (2012). Rectal cancer. *J Natl Compr Canc Netw*, 10(12), 1528-60.
 50. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA (2013). Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw*, 11(2), 141-52; quiz 152.
 51. Chen N, Chawla SP, Chiorean EG, Read WL, Gorbaty M, Mita AC, Yung L, Bryan P, McNally R, Renschler MF, **Sharma S** (2013). Phase I study to assess the pharmacokinetics and the effect on

- cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors. *Cancer Chemother Pharmacol*, 71(4), 1083-94.
52. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA (2013). Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw*, 11(5), 519-28.
 53. Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, **Sharma S**, Capecchi MR (2013). SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. *Oncogene*, 32(18), 2365-71, 2375.e1-5.
 54. Ng K, Tabernero J, Hwang J, Bajetta E, **Sharma S**, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS (2013). Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. *Clin Cancer Res*, 19(14), 3987-95.
 55. **Sharma S**, Beck J, Mita M, Paul S, Woo MM, Squier M, Gadbar B, Prince HM (2013). A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. *Invest New Drugs*, 31(4), 974-85.
 56. Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles L, Gordon MS, **Sharma S**, Infante JR, Lorusso PM, Pande G, Krachey EC, Blackman SC, Carson SW (2013). Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. *J Pharm Sci*, 102(9), 3100-9.
 57. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, **Sharma S** (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. *Invest New Drugs*, 31(5), 1257-64.
 58. Sankar S, Bell R, Stephens B, Zhuo R, **Sharma S**, Bearss DJ, Lessnick SL (2013). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. *Oncogene*, 32(42), 5089-100.
 59. Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, **Sharma S** (2013). High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. *J Med Chem*, 56(23), 9496-508.
 60. Theisen ER, Gajiwala S, Bearss J, Sorna V, **Sharma S**, Janat-Amsbury M (2014). Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. *BMC Cancer*, 14, 752.
 61. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, **Sharma S**, Thompson I, Vogelzang NJ, Roth BJ (2014). Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. *J Clin Oncol*, 32(2), 129-60.
 62. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, **Sharma S** (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. *Clin Cancer Res*, 20(2), 480-9.
 63. **Sharma S**, de Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L, Bilic S, Parker K, Goldbrunner M, Scott JW, Burris HA 3rd (2014). Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. *Invest New Drugs*, 32(1), 135-44.
 64. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, **Sharma S**, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA (2014). Ceritinib in ALK-rearranged non-small-cell lung

- cancer. *N Engl J Med*, 370(13), 1189-97.
65. Fiskus W, **Sharma S**, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. *Mol Cancer Ther*, 13(5), 1142-54.
 66. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, **Sharma S**, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semiond D, Chadjaa M, Shen L, Wade JL (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol*, 73(6), 1241-52.
 67. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA (2014). Colon cancer, version 3.2014. *J Natl Compr Canc Netw*, 12(7), 1028-59.
 68. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchiatti L, Devaraj SG, Shah B, **Sharma S**, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014). Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. *Oncotarget*, 5(14), 5637-50.
 69. Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, **Sharma S**, Lessnick SL (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. *Clin Cancer Res*, 20(17), 4584-97.
 70. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, **Sharma S** (2014). Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. *Lung Cancer*, 85(3), 429-34.
 71. Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, **Sharma S**, Tricot G, Zhan F, Bearss DJ (2014). Inhibition of Nek2 by Small Molecules Affects Proteasome Activity. *Biomed Res Int*, 2014, 13.
 72. Fiskus W, **Sharma S**, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN (2014). BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. *Mol Cancer Ther*, 13(10), 2315-27.
 73. **Sharma S**, Britten CD, Mortimer J, Kulkarni S, Quinlan M, Liu A, Scott JW, George D (2014). The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. *Cancer Chemother Pharmacol*, 74(4), 867-74.
 74. Machiels JP, Staddon A, Herremans C, Keung C, Bernard A, Phelps C, Khokhar N, Knoblauch R, Parekh T, Dirix L, **Sharma S** (2014). Impact of Cytochrome P450 3A4 Inducer and Inhibitor on the Pharmacokinetics of Trabectedin in Patients with Advanced Malignancies: Open-label, Multicenter Studies. *Cancer Chemother Pharmacol*, 74(4), 729-37.
 75. Slingerland M, Hess D, Clive S, **Sharma S**, Sandstrom P, Loman N, Porro MG, Mu S, Waldron E, Valera SZ, Gelderblom H (2014). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. *Cancer Chemother Pharmacol*, 74(5), 1089-98.
 76. Fiskus W, **Sharma S**, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN (2014). Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. *Leukemia*, 28(11), 2155-64.
 77. Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, **Sharma S** (2014). Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. *Invest New Drugs*,

- 32(6), 1181-7.
78. Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, **Sharma S**, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW (2014). Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. 2015 Apr;55(4):392-400. doi: 10.1002/jcph.437. Epub 2014 Dec 30. *J Clin Pharmacol*, 55(4), 392-400.
 79. **Sharma S**, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S (2015). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. *Cancer Chemother Pharmacol*, 75(1), 87-95.
 80. Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, **Sharma S** (2015). Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. *Anticancer Res*, 35(3), 1567-73.
 81. Infante JR, Ramanathan RK, George D, Tan E, Quinlan M, Liu A, Scott JW, **Sharma S** (2015). A randomized, crossover phase I study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). *Cancer Chemother Pharmacol*, 75(4), 729-37.
 82. Fiskus W, **Sharma S**, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN (2015). Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. *Leukemia*, 29(6), 1267-78.
 83. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, **Sharma S**, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D (2015). Rectal Cancer, Version 2.2015. *J Natl Compr Canc Netw*, 13(6), 719-28; quiz 728.
 84. Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, **Sharma S** (2015). Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime beta-Catenin Pathway Inhibitors. *J Med Chem*, 58(15), 5854-62.
 85. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, **Sharma S**, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN (2015). Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. *Blood*, 126(13), 1565-74.
 86. Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, **Sharma S** (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. *Invest New Drugs*, 33(6), 1217-24.
 87. Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, **Sharma S** (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. *Cancer Chemother Pharmacol*, 77(2), 299-308.
 88. Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, **Sharma S**, Bradner JE, Bhalla KN (2016). HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. *Leukemia*, 30(2), 504-8.
 89. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, **Sharma S**, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol*, 17(4), 452-63.
 90. Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, **Sharma S** (2016). Phase II

- study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. PMID: 26897615 doi: 10.1007/s10637-016-0333-z. Epub 2016 Feb 20. *Invest New Drugs*, 34(2), 243-52.
91. Andrade D, Velinder M, Singer J, Maese L, Bareyan D, Nguyen H, Chandrasekharan MB, Lucente H, McClellan D, Jones D, **Sharma S**, Liu F, Engel ME (2016). SUMOylation Regulates Growth Factor Independence 1 in Transcriptional Control and Hematopoiesis. *Mol Cell Biol*, 36(10), 1438-50.
 92. Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, **Sharma S** (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. *Cancer Chemother Pharmacol*, 78(3), 491-500.
 93. Massard C, Gordon MS, **Sharma S**, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH (2016). Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. *J Clin Oncol*, 34(26), 3119-25.
 94. Gupta N, Hanley MJ, Venkatakrishnan K, Wang B, **Sharma S**, Bessudo A, Hui AM, Nemunaitis J (2016). The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. *J Clin Pharmacol*, 56(10), 1288-95.
 95. Velinder M, Singer J, Bareyan D, Mezmarich J, Tracy CM, Fulcher JM, McClellan D, Lucente H, Franklin S, **Sharma S**, Engel ME (2016). GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1. *Biochem J*, 473(19), 3355-69.
 96. Shrestha G, MacNeil SM, McQuerry JA, Jenkins DF, **Sharma S**, Bild AH (2016). The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. *Semin Cell Dev Biol*, 58, 108-117.
 97. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, **Sharma S**, Coarfa C, Qiu P, Verstovsek S, Bhalla KN (2016). BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. LID - 10.1038/leu.2016.260 [doi]. (Epub ahead of print) *Leukemia*.
 98. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, **Sharma S**, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. *Cancer Chemother Pharmacol*, 78(5), 1059-1071.
 99. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, **Sharma S** (2016). Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. *Cancer Chemother Pharmacol*, 78(5), 921-927.
 100. Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, **Sharma S**, Korn WM (2016). A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. (Epub ahead of print) *Invest New Drugs*.
 101. Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, **Sharma S** (2016). Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. *Prostate Cancer Prostatic Dis*, 19(4), 349-357.

NON PEER-REVIEWED JOURNAL ARTICLES

1. **Sharma S** (2001). Oral chemotherapy for colorectal cancer (An update). *Oncology Spectrums*, 2.
2. Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, **Sharma S** (2015). N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. *Oncoscience*, 2(3), 285-93.

REVIEW ARTICLES

1. Bailey H, Stenehjem DD, **Sharma S** (2015). Panobinostat for the treatment of multiple myeloma: the evidence to date. [Review]. *J Blood Med*, 6, 269-76.
2. Shrestha G, MacNeil SM, McQuerry JA, Jenkins DF, **Sharma S**, Bild AH (2016). The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. [Review]. *Semin Cell Dev Biol*, 58, 108-17.

BOOK CHAPTERS

1. Weiss GR, Burris HA, Eckhardt SG, Rodriguez GI, **Sharma S**, Valley A (1997). New Anticancer Agents. In Pinedo HM, Longo DL, Chabner BA (Eds.), *Cancer chemotherapy and biologic response modifiers* (pp. 179-194). Amsterdam: Elsevier.
2. Britten C, Hammond L, Hidalgo M, Rothenberg ML, Sharma A, **Sharma S**, Siu L, Villalona-Calero M, Weiss GR (1999). New Anticancer Agents. In Pinedo HM, Longo DL, Chabner BA (Eds.), *Cancer chemotherapy and biologic response modifiers Annual 18* (pp. 178-209). Amsterdam: Elsevier.
3. **Sharma S**, Willett C, Haller D, Saltz LB, Tepper J (2001). Colorectal cancer: Management of locoregional disease. In Levin B, Daly JM, Tepper JE, Kern SE, Kelsen DP (Eds.), *Gastrointestinal Oncology: Principles and Practice* (pp. 755-781). Philadelphia: Lippincott.

Other (Commentary/Letters/Editorials/Case Reports/Video/Film)

Case Reports

1. Webber NP, **Sharma S**, Grossmann AH, Shaaban A, Jones KB, Layfield LJ, Randall RL (2010). Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases. *J Clin Oncol*, 28(29), e545-9.

Editorials

1. **Sharma S** (2002). Topoisomerase II inhibitors--teaching old dogs new tricks. *Cancer Invest*, 20(4), 596-7.
2. **Sharma S** (2009). Phase 1 trials in oncology in India: the clear case for innovation. *J Cancer Res Ther*, 5(2), 69-70.

Letters

1. **Sharma S** (1996). Paclitaxel and Doxorubicin in Metastatic Breast Cancer (Letter) [Letter to the editor]. *J Clin Oncol*, 14(4), 1403.
2. **Sharma S** (2006). Phase I trials may not need to be viewed as extraordinarily different from other clinical research [Letter to the editor]. *J Clin Oncol*, 24(28), e47.

Patents

1. Bearss D, Vankayalapati H, Sorna V, Warner S, **Sharma S** (2012). "Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDK1 Kinase". U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.
2. Bearss D, Vankayalapati H, Mollard A, Warner S, **Sharma S** (2014). Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase. U.S. Patent No. 8,901,120. Washington, D.C.:U.S. Patent and Trademark Office.
3. Vankayalapati H, Sorna V, Warner S, Stephens B, Bearss D, **Sharma S** (2012). Substituted (E)-N'-(1-Phenylethylidene)Benzohydrazide Analogs as Histone Demethylase Inhibitors". U.S. Patent No. 8,987,335. Washington, D.C.:U.S. Patent and Trademark Office.

4. Bearss D, Vankayalapati H, Sorna V, Warner S, **Sharma S** (2015). "Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors". U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.
5. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, **Sharma S** (2016). Substituted N-(3(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors. U.S. Patent No. US 9,296,703, B2. Washington, D.C.:U.S. Patent and Trademark Office.

Video/Film/CD/Web/Podcast

1. **Sharma S** (1997). Drug Resistance in Oncology [Web]. ASCO Online. Available: http://www.asco.org/prof/oc/html/m_sharma2.htm.
2. **Sharma S** (1997). Anticancer Drug Development Guide [Web]. ASCO Online. Available: http://www.asco.org/prof/oc/html/m_sharma1.htm.
3. **Sharma S** (2000). ASCO Journal Club [Web]. Available: http://www.asco.org/prof/oc/html/m_perou0500.htm.

PUBLISHED ABSTRACTS

1. Raymond E, Soda H, **Sharma S**, Sun D, Izbicka E, Von Hoff DD (1997). *DNA-intercalating drugs that down-regulate telomerase and interact with telomeric repeats in human cancer cells* [Abstract]. *Proc Amer Assoc Cancer Res*, 38(505), A3387.
2. **Sharma S**, Raymond E, Soda H, Izbicka E, Von Hoff DD (1997). *Telomerase activity during cell cycle in a lymphoma cell line*. *Proc Amer Assoc Cancer Res* [Abstract]. 38(504), A3383.
3. Raymond E, Davidson K, Soda H, **Sharma S**, Sun D, Izbicka E, Von Hoff DD (1997). *Effects of DNA-intercalating drugs on telomerase activity in cultures human cancer cells*. *San Antonio* [Abstract]. *Proc Symp Cancer Res*, 17, A13.
4. **Sharma S**, Raymond E, Soda H, Izbicka E, Sun D, Von Hoff DD (1997). *A model for telomerase inhibition in lymphomas* [Abstract]. *Proc Internat Cong Biolog Resp Modif*, 73, A21.
5. Eckardt G, **Sharma S**, Kuhn J, Rizzo E, Campbell E, Ho P, Weiss G, Hammond L, Kraynak M, Von Hoff DD, Rowinsky E (1997). *A phase I and pharmacokinetic study of the rebeccamycin analog NSC 655649 in patients with advanced cancer* [Abstract]. *Proc ASCO*, 16(216a), A759.
6. Raymond E, **Sharma S**, Sun D, Champlin RE, Soda H, Boldt DH, Von Hoff DD (1997). *Detection of cancer cells with PCR-telomerase assay in human tumor biopsies* [Abstract]. *Proc ASCO*, 16(93a), A327.
7. Soda H, Raymond E, **Sharma S**, Davidson K, Izbicka E, Von Hoff DD (1997). *Effects of exogenous androgen on telomerase activity in human prostate cancer cells* [Abstract]. *Proc Amer Assoc Cancer Res*, 38(504), A3384.
8. Raymond E, Sun D, Champlin R.E., **Sharma S**, Soda H, Izbicka E, Von Hoff DD (1997). *Identification of a (TTAGGG)₃ transferase activity which competes with telomerase in normal blood and bone marrow cell harvests* [Abstract]. *Proc Amer Assoc Cancer Res*, 38(637), A4275.
9. Raymond E, **Sharma S**, Sun D, Champlin R, Soda H, Boldt DH, Hilsenbeck S, Von Hoff DD (1997). *Value of PCR-telomerase assay to detect cancer cells in human biopsies*. *San Antonio* [Abstract]. *Proc Symp Cancer Res*, 19, A23.
10. **Sharma S**, Rowinsky E, Thurman A, Drengler R, Kraynak M, Siu L, Hidalgo M, Ayelsworth C, Hanham A, fisher E, Von Hoff DD, Eckhardt SG (1998). *A phase I and pharmacokinetic (PK) study of vesnarinone, an inducer of differentiation and apoptosis, in combination with gemcitabine*. *Proc ASCO* [Abstract]. 17, A803.
11. Diab S, Britten C, Eckhardt SG, Hammond L, Elledge R, Siu L, **Sharma S**, Hidalgo M, Ayelsworth C, Razvillas B, Kraynak M, Baker S, Smith R, Averbuch S, Von Hoff DD, Rowinsky E (1998). *Phase I and pharmacokinetic (PK) study of the nonpolyglutamated thymidylate synthetase (TS) inhibitor ZD 9331 given as a 30 minute infusion every 3 weeks*. *Proc ASCO* [Abstract]. 17, A869.
12. O'Reilly E, Ilson D, Schwartz G, Tong W, Fata F, Kemeny N, Sherwin K, **Sharma S**, Kelsen D

- (1999). *A phase I study of combination gemcitabine(gem) and irinotecan (CPT-11) in patients with refractory solid tumors. Proc ASCO [Abstract]. 18, A674.*
13. Ilson D, Enzinger P, Saltz L, O'Reilly E, **Sharma S**, Gollub M, Huang Y, Gonzalez G, Kelsen D (1999). *Phase II weekly Irinotecan+Cispatin in advanced gastric cancer. Proc ASCO [Abstract]. 18, A994.*
 14. **Sharma S**, Kemeny N, Schwartz GK, Kelsen D, O'Reilly E, Ilson D, Coyle J, De Jager RL, Kleban S, Hollywood E, Saltz LB (1999). *A phase I study of topoisomerase inhibitor DX-8951f (Exatecan Mesylate) given as three weekly 24-hour infusions every four weeks. Proc ASCO [Abstract]. 18, A684.*
 15. Minsky BD, O'Reilly E, Wong D, **Sharma S**, Paty P, Guillem J, Cohen A, Ilson D, Hollywood E, Semple D, Kleban S, Kelsen D, Saltz LB (1999). *Daily low dose irinotecan (CPT-11) plus pelvic irradiation as preoperative treatment of locally advanced rectal cancer. Proc ASCO [Abstract]. 18, A1023.*
 16. Ilson D, **Sharma S**, Kemeny N, Maki R, Schrag D, Schwartz G, O'Reilly E, Kelsen D, Ochoa M, Gonzalez G, Saltz L (2000). *A phase I trial of cisplatin, irinotecan and escalating doses of weekly one hour paclitaxel in patients with solid tumor malignancies [Abstract]. Proc Am Soc Clin Oncol, 19, A1162.*
 17. **Sharma S**, Britten C, Spriggs D, Rosen N, Pezzulli S, Patnaik A, Kher U, Arena C, Deutsch P, Yao S, Rowinsky E (2000). *A phase I and PK study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel [Abstract]. Proc Am Soc Clin Oncol, 19, A719.*
 18. O'Reilly E, Hammond L, **Sharma S**, Aird S, Rowinsky E, Kelvin J, Kelsen D, Ochoa L, Zitelli A, De Jager R (2000). *A phase II trial of exatecan mesylate (DX- 8951f, DX) in advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol, 19, A1170.*
 19. **Sharma S**, Knight RD, Hollywood EH, Locker PK, Compton LD, Archinal AE, Duncan BA, Eli MP, Schaff LJ, Miller LL, Saltz LB (2001). *A phase I and pharmacokinetic study of powder-filled capsule formulation of irinotecan (CPT-11) given daily for 14 days every 3 weeks in patients with advanced solid tumors [Abstract]. Proc Am Soc Clin Oncol, 20, A407.*
 20. O'Reilly E, Hoff PM, Mani S, Schawartz GK, Aird S, **Sharma S**, Hazelwood B, Kelvin J, DeJager R, Kelsen D (2001). *A phase I study of DX-8951f (Exatecan Mesylate) and gemcitabine in advanced solid tumors [Abstract]. Proc Am Soc Clin Oncol, 20, A412.*
 21. D'Adamo D, Hammond L, Donehower R, **Sharma S**, Aird S, Kelsen DP, Ochoa L, Rowinsky E, DeJager R, O'Reilly EM (2001). *Final results of a phase II study of DX-8951f (Exatecan Mesylate, DX) in advanced pancreatic cancer [Abstract]. Proc Am Soc Clin Oncol, 20, A532.*
 22. Maki RG, Ilson DH, O'Reilly E, **Sharma S**, Schrag D, Schwartz GK, Kelsen DP, Gonzalez G, Saltz LB (2001). *Phase I trial of cisplatin, irinotecan and weekly paclitaxel in patients with solid tumor malignancies [Abstract]. Proc Am Soc Clin Oncol, 20, A430.*
 23. Doroshow JH, Synold T, Longmate J, Takimoto C, Gandara D, Mani S, Remick S, **Sharma S**, Hamilton A, Mulerkin D, Ramanathan R, Graham M, Price W, Ivy P (2001). *Phase I and pharmacokinetic trial of oxaliplatin in solid tumor patients with varying degrees of liver dysfunction [Abstract]. Proc Am Soc Clin Oncol, 20, A449.*
 24. Graham M, Takimoto CH, Rmick S, Thomas R, Ramanathan RK, Mani S, **Sharma S**, Doroshow JH, Mulerkin D, Hamilton A, Grea J, Schuler B, Greenslade D, Ivy SP (2001). *A phase I study of oxaliplatin in renal dysfunctio [Abstract]. Proc Am Soc Clin Oncol, 20, A267.*
 25. White D, Kris M, Otterson GA, Imondi A, Allen JN, **Sharma S** (2001). *Phase I clinical and pharmacologic study of inhaled doxorubicin in adults with advanced solid tumors affecting the lung [Abstract]. Proc Am Soc Clin Oncol, 20, A2739.*
 26. Abou-Alfa GK, O'Reilly EM, Rowinsky EK, Patt Y, Schwartz GK, **Sharma S**, Siegel E, Eckhardt SG, Becerra C, Jakubowitz J, Duggal A, Lubicz S, DeJager R (2002). *Final results of a phase II study of DX-8951f (DX, exatecan mesylate) in biliary tree cancers [Abstract]. Proc Am Soc Clin*

- Oncol*, 21, A561.
27. O'Reilly EM, Lenzi R, Mani S, Schwartz G, **Sharma S**, Kelsen DP, Levin A, Danna M, Bridget H, DeJager R (2002). *Final results of a phase I study of DX-8951f (DX) and gemcitabine (Gem) in advanced solid tumor malignancies* [Abstract]. *Proc Am Soc Clin Oncol*, 21, A394.
 28. Shah MA, Kortmansky J, Gonen M, O'Reilly EM, **Sharma S**, Saltz LB, Lefkowitz RA, Kelsen DP, Endres S, Welch M, Tong W, Schwartz GK (2002). *A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F)* [Abstract]. *Proc Am Soc Clin Oncol*, 21, A373.
 29. Wang E, Anderson S, Hummer A, Caron P, Ilson D, Kelsen D, **Sharma S** (2002). *Dose intensity and toxicity of CPT-11 in geriatric metastatic colorectal cancer patients* [Abstract]. *Proc Am Soc Clin Oncol*, 21, A1448.
 30. Ilson D, O'Reilly EM, **Sharma S**, Saltz L, Maki RG, Schrag D, Joseph J, Kelsen D (2002). *A phase I trial of cisplatin, fluorouracil, and escalating doses of weekly irinotecan in patients with solid tumor malignancy* [Abstract]. *Proc Am Soc Clin Oncol*, 21, A566.
 31. **Sharma S**, White D, Kris M, Otterson G, Allen J, Murren J, Schiller J, Sandler A, Ryan C, Ratain M, Ramirez J, Imondi A (2002). *A multicenter phase I clinical and pharmacologic study of inhaled doxorubicin (Resmycin) in adults with advanced solid tumors affecting the lungs* [Abstract]. *Proc Am Soc Clin Oncol*, 21, A1204.
 32. Mita C, Hammond LA, Lockhart AC, Shah M, Curtright J, Chen T, Dugan M, Cooper W, Chaffin M, **Sharma S**, Rowinsky EK, Rothenberg ML (2003). *A phase I and pharmacokinetic study of XA296A (discodermolide) administered once every three weeks in adult patients with advanced solid malignancies*. *Proc AACR-NCI-EORTC* [Abstract]. 111-112, A252.
 33. Shah M, Dauffenbach L, Kerfoot CA, Cohen P, Culver KW, **Sharma S**, Wartmann M (2003). *A comparative study of two novel, non-taxane microtubule stabilizing agents (XAA296A and EPO906A) utilizing the extreme drug resistance (EDR) assay in paclitaxel-sensitive or paclitaxel resistant breast and ovarian cancers*. *Proc AACR-NCI-EORTC* [Abstract]. 114, A262.
 34. Lee L, McSheehy P, Morgan B, Laird G, Allegrini P, Cozens R, Dugan M, Laurent D, Lebowitz D, **Sharma S** (2003). *Biomarkers for the assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK/ZK 22584 (PTK/ZK): Comparison of preclinical data with results in Phase I studies*. *Proc AACR-NCI-EORTC* [Abstract]. 184, B268.
 35. Azzoli G, Krug LM, Miller VA, **Sharma S**, Gomez J, Kris MGK, Ginsberg M, Baez V, Henry R, Tyson L, Dunne M, Pizzo B, Sirotnak FM (2003). *Phase I study of 10-propargyl-deazaaminopterin (PDX) plus docetaxel or paclitaxel in patients with advanced cancer*. *Proc AACR-NCI-EORTC* [Abstract]. 95, A182.
 36. Giles FJG, Fischer T, Cortes J, Beck J, Ravandi-Kashani F, Garcia-Manero G, Kantarjian HM, Peng B, Rae PE, Laird G, **Sharma S**, Dugan M, Albitar M, Bhalla K (2004). *A Phase I/II study of Intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hematologic malignancies* [Abstract]. *Blood*, 499A, A1802.
 37. **Sharma S**, Vogelzang N, Wong B, Adams C, Manno P, Welborne K, Giraud Y (2006). *Preclinical and clinical investigation of histone deacetylase inhibitor valproic acid given orally in androgen independent prostate cancer*. *Proc ASCO*. 18S (June 20 Supplement) [Abstract]. 18S, 14614.
 38. Papadimitrakopoulou V, Soria J-C, **Sharma S**, Douillard J-Y et al (2007). *A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)*. *Suppl; abstr 7589* [Abstract]. *J Clin Oncol*, 25, 18S.
 39. Fiscus RF, Bathina M, Johlfis MJ, **Sharma S**, Vogelzang NJ (2007). *ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells* *Proc AACR, Ab LB-43* [Abstract].
 40. Nogova L, Zander T, **Sharma S**, Gross SH et al (2007). *Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with recurrent non-small cell lung cancer (NSCLC): Use of 18F fluorodeoxyglucose positron-emission tomography (FDG-PET) in evaluation of the*

- pharmacodynamic effect* [Abstract]. *J Thor Oncol*, 2(8 Supplement 4), S583.
41. Symanowski J, Giraud Y, Dino P, Atadja P, Vogelzang N, **Sharma S** (2007). *Synergistic interaction between histone deacetylase (HDAC) inhibitor LBH589 and Cisplatin (CDDP) in mesothelioma cell lines* *Proc AACR*, Ab LB-327 [Abstract].
 42. Papadimitrakopoulou V, Soria J-C, **Sharma S**, Douillard J-Y et al (2007). *A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)* [Abstract]. *J Thor Oncol*, 2(8 Supplement 4), S359-A360.
 43. Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, **Sharma S**, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL (2007). *Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function* [Abstract]. *Clin Cancer Res*, 13(16), 4832-9.
 44. **Sharma S**, Vogelzang N, Beck J, et al (2007). *Phase I pharmacokinetic and pharmacodynamic study of once-weekly i.v. panobinostat (LBH589)*. *ECCO Poster presented. Barcelona, Spain (abstr 702)* [Abstract].
 45. Yee L, **Sharma S**, Breitz H, Karlin D, Phillips A, Houston S, Saleh M (2008). *Phase I randomized crossover oral picoplatin bioavailability pharmacokinetics and pharmacodynamics study* *Proc AACR*; (209) [Abstract].
 46. **Sharma S**, de Vries EG, Infante JR, Oldenhuis C, Chiang L, Bilic S, Goldbrunner M, Scott JW, Burris HA (2008). *Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors*. *Abstr 3538* [Abstract]. *J Clin Oncol*, 26 *Suppl.*
 47. Wong BY, Shapiro GI, Gordon MS, Borad MJ, Eder JP, Tibes R, Mendelson DS, Wasserman E, Kawabe T, **Sharma S** (2008). *Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts)*. *Abstr 2528* [Abstract]. *J Clin Oncol*, 26 *Suppl.*
 48. Abhyankar VV, **Sharma S**, Trowbridge RC, Robles RL, Tarazi JR, Kim S, Tortorici M, Hee B., Burgess RE (2008). *Axitinib (AG-013736) in combination with FOLFOX and bevacizumab (Bev) in patients (pts) with metastatic solid tumors: A phase I study*. *Abstr 4112* [Abstract]. *J Clin Oncol*.
 49. Modur V, Motwani M, Scott JW, Krajcovich L, Infante JR, Burris HA, **Sharma S**, Goldbrunner M, Barrett JC, Gietema JA (2008). *M30 and M65 assessments demonstrate pro-apoptotic effect of LBY135, a monoclonal antibody agonist to DR5*. *Abstr 14587* [Abstract]. *J Clin Oncol*, 26 *suppl.*
 50. Fuchs CS, Tabernero JM, Hwang J, Bajetta E, **Sharma S**, DelPrete SA, Arrowsmith ER, Ryan DP, Hoosen S (2009). *Multicenter phase II study of RAD001 in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC)* [Abstract]. *Proc Gastrointestinal Cancers Symposium*.
 51. Senzer NN, Matsuno K, Yamagata N, Tadashi Fujisawa T, Ernesto Wasserman E, Sutherland W, **Sharma S**, Phan A (2009). *MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics* [Abstract]. *Mol Cancer Ther*, 8(12 *Suppl.*)
 52. Burris H, Rodon J, **Sharma S**, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl H, Baselga J (2010). *First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors* [Abstract]. *J Clin Oncol*, 28(15).
 53. Borgstein NG, **Sharma S**, Bendell JC, Gordon MS, Hurwitz H, Solban N, Mitchell D, Pearsall S, Condon CH, Sherman ML (2010). *Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma* [Abstract]. *J Clin Oncol*, 28(7).
 54. **Sharma S**, Sausville EA, LoRusso P, Vogelzang NJ, Samlowski WE, Carter J, Forman K, Bever S, Messmann RA (2010). *A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle* [Abstract]. *J Clin Oncol*, 28(7).
 55. Velleca M, Miller L, **Sharma S**, Gordon M, Brittelli D, Elkin L, Govindarajan R, Klein U, Mitchell

- S, Nandhagopal N, Qian D, Qian X, Stephen T, Srinivasa S, Stern W (2010). *Preclinical and phase I trial results of JI-101, a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR β* [Abstract]. *Proc AACR*.
56. Stephens B, Warner S, Vankayalapati H, Bearss D, **Sharma S** (2011). *Identification of CIT-0665, a novel inhibitor of LSD1* [Abstract]. *Poster Proc AACR: (LB-187)*.
 57. Agarwal N, Sahu M, Abhyankar DJ, Werner TL, Benjamin B, Srinivas R, **Sharma S** (2011). *A drugdrug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors* [Abstract]. *J Clin Oncol*, 29(suppl; abstr e15077).
 58. Verma A, Frazer JK, Trakhimets A, Heaton W, Bearss J, Warner S, Bearss D, **Sharma S** (2011). *A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia* [Abstract]. *Oral and Poster Presentation ASH Annual Meeting*.
 59. Fiskus W, Smith J, Mudunuru U, Hembruff S, Reyes R, Abhyankar S, McGuirk J, Aljitawi O, Ganguly S, Horrigan S, **Sharma S**, Bhalla KN (2011). *Treatment with β -Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells* [Abstract]. *Oral and Poster ASH Annual Meeting*.
 60. Wade JL, Dakhil SR, Baron AD, Rottey S, Millard FE, Daugaard G, Machiels J, Conkright WA, **Sharma S**, Soetekouw P, Yachnin J, Sengeløv L, van Veldhuizen P, Agarwala SS, Quyen Nguyen TX, Chadjaa M, Maison-Blanche P (2012). *A QTc study of cabazitaxel in patients with advanced solid tumors* [Abstract]. *Poster ASCO Genitourinary Cancers Symposium*.
 61. Shaw AT, Camidge DR, Felip E, **Sharma S**, Tan DSW, Kim DW, De Pas T, Vansteenkiste JF, Santor A, Liu G, Chow L, Goldwasser M, Lau Y, Boral AL, Mehra R (2012). *Results of the first-in-human Phase I study of the ALK inhibitor LDK378 in advanced malignancies* [Abstract]. *Oral presentation ESMO Congress*.
 62. **Sharma S**, Ramanathan RK, George DJ, Quinlan M, Kulkarni S, Homsy A, Scott JW, Infante JR (2013). *A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258)* [Abstract]. *Poster ASCO Annual Meeting*.
 63. Shaw AT, Mehra R, Kim DW, Felip E, Quan Man Chow L, Camidge DR, Shao-Weng Tan D, Vansteenkiste JF, **Sharma S**, De Pas T, Wolf J, Katayama R, Lau YYY, Goldwasser M, Boral A, Engelman JA (2013). *Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC* [Abstract]. *Oral Presentation Clinical Science Symposium ASCO Annual Meeting*.
 64. Machiels JP, Staddon AP, Herremans C, Keung C, Bernard A, Phelps C, Aymes AL, Khokhar NZ, Knoblauch RE, Parekh TV, Dirix L, **Sharma S** (2014). *Effects of cytochrome P450 inducer and inhibitor coadministration on the pharmacokinetics of trabectedin in patients with advanced or metastatic solid tumors* [Abstract]. *ASCO J Clin Oncol*, 32(suppl; abstr e13520).
 65. Tabernero J, Van Geel R, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens F, **Sharma S**, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Demuth T, Schellens JH (11/21/2014). *Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α -specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer* [Abstract]. *Oral presentation EORTC-NCI-AACR Symposium*.
 66. Schellens JH, VanGeel R, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens F, **Sharma S**, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Demuth T, Tabernero J (2015). *Phase Ib Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α -specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer* [Abstract]. *Oral and Poster Presentation Proc AACR*.
 67. Gupta S, Weston A, Bearss J, Soldi R, **Sharma S** (2015). *Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells* [Abstract]. *Poster Proc AACR*.

UNPUBLISHED POSTER PRESENTATIONS

1. **Sharma S**, Sorna V, Warner S, Call L, Bearss D, Vankayalapati H (2011). *Fragment-based design, synthesis and biological evaluation of a series of novel PDK1 inhibitors*. Poster session presented at American Association for Clinical Research, Orlando.
2. Call L, Mollard A, Wade M, Bearss J, Yang M, Verma A, Vankayalapati H, Hansen M, Bearss D, **Sharma S**, Warner S (2011). *Targeting the Axl tyrosine kinase receptor in pancreatic cancer*. Poster session presented at American Association for Clinical Research, Orlando.
3. Stephens BJ, Warner SL, Vankayalapati H, Bearss DJ, **Sharma S** (2011). *Identification of CIT-0665, a novel inhibitor of LSD1*. Poster session presented at American Association for Clinical Research, Orlando.
4. Bendell JC, Gordon MS, Hurwitz H, Condon CH, Wilson D, Yang Y, Kumar R, Pearsall RS, Solban N, Attie KM, Sherman ML, **Sharma S** (2011). *A Phase I Dose Escalating Study of ACE-041, a Novel Inhibitor of ALK1-mediated Angiogenesis, in Patients with Advanced Solid Tumors*. Poster session presented at American Association for Cancer Research, Orlando.
5. Gilcrease G, Wade M, Mullangi R, Srinivasa S, Northrup J, Govindarajan R, **Sharma S** (2011). *Preclinical combination strategies for development of JI-101, a selective inhibitor of Ephrin B4, VEGF R2, and PDGF-R?* Poster session presented at American Association for Clinical Research, Orlando.
6. Grossmann K, Blankenship M, Akerley W, Terrazas M, Kosak K, Boucher K, Buys S, Jones K, Werner T, Agarwal N, Weis J, **Sharma S**, Ward J, Shami P (2011). *A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver*. Poster session presented at American Association for Clinical Research, Orlando.
7. Fiskus W, **Sharma S**, Rao R, Balusu R, Tao J, Sotomayor E, Atadja P, Ganguly S, Bearss D, Bhalla K (2011). *Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells*. Poster session presented at American Association for Clinical Research, Orlando.
8. Mollard A, Warner S, Call L, Wade M, Bearss J, Verma A, Yang M, **Sharma S**, Bearss D, Vankayalapati H (2011). *Homology structure-based design, synthesis and biological evaluation of a series of novel Axl and Mer kinase inhibitors*. Poster session presented at American Association for Clinical Research, Orlando.
9. **Sharma S**, Kurzrock R, Gouw L, Hong DS, Jones K, Zhou X, Shi H, Fingert H, Falchook GS (2011). *Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies*. Poster session presented at American Society of Clinical Oncology, Chicago.
10. Chen N, Chawla S, Chiorean EG, Read WL, Gorbaty M, Mita A, Yung L, McNally R, Renschler MF, **Sharma S** (2011). *A Phase I Study to Assess Pharmacokinetics, QT/QTc Effect, and Safety of Amrubicin in Patients With Advanced Solid Tumors*. Poster session presented at American Society of Clinical Oncology, Chicago.
11. Bendell JC, Gordon MS, Hurwitz H, Condon CH, Wilson D, Yang Y, Kumar R, Pearsall RS, Solban N, Attie KM, Sherman ML, **Sharma S** (2011). *A Phase I Dose Escalating Study of ACE-041, a Novel Inhibitor of ALK1-mediated Angiogenesis, in Patients with Advanced Solid Tumors*. Poster session presented at American Society of Clinical Oncology, Chicago.
12. Fiskus W, Smith J, Mudunuru U, Hembruff S, Reyes R, Abhyankar S, McGuirk J, Aljitawi O, Ganguly S, Horrigan S, **Sharma S**, Bhalla KN (2011). *Treatment with β -Catenin Antagonist BC2059 Exhibits Single Agent Efficacy and Exerts Superior Activity with Tyrosine Kinase Inhibitor (TKI) or Histone Deacetylase (HDAC) Inhibitor Against Human AML, CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells*. Poster session presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, San Francisco.

13. Stephens BJ, Sorna V, Theisen E, Vankayalapati H, Warner SL, Bearss DJ, **Sharma S** (2011). *HCI-2528 is a potent inhibitor of LSD1 with improved drug-like characteristics*. Poster session presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, San Francisco.
14. Verma A, Frazer JK, Trakhimets A, Heaton W, Bearrs J, Warner S, Bearrs D, **Sharma S** (2011). *A Novel Dual AXL/Mertk and Aurora Kinase Inhibitor Active Against T Cell Acute Lymphoblastic Leukemia*. Poster session presented at American Society of Hematology, San Diego.
15. Gilcrease GW, Garrido-Laguna I, Jones K, Mitchell M, Davis T, Wade M, Weis J, Whisenant J, **Sharma S** (2012). *Phase I study of mFOLFOX-6, bevacizumab and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer*. Poster session presented at ASCO Gastrointestinal Cancers Symposium, San Francisco.
16. Wade JL, Dakhil SR, Baron AD, Rottey S, Millard FE, Daugaard G, Machiels J, Conkright WA, **Sharma S**, Soetekouw P, Yachnin J, Sengeløv L, van Veldhuizen P, Agarwala SS, Quyen Nguyen TX, Chadjaa M, Maison-Blanche P (2012). *A QTc study of cabazitaxel in patients with advanced solid tumors*. Poster session presented at ASCO Genitourinary Cancers Symposium, San Francisco.
17. **Sharma S**, Britten CD, Mortimer J, Kulkarni S, Quinlan M, Homsy A, Tan E, Anand S, Liu A, Scott J, George D (04/07/2013). *The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors*. Poster session presented at American Association for Cancer Research, Washington, DC.
18. Gupta N, Venkatakrishnan K, Noe DA, Hanley MJ, Yu J, Bessudo A, **Sharma S**, Strother RM, Shou Y, Nemunaitis JJ (2013). *A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma*. Poster session presented at American Society of Clinical Oncology, Chicago.
19. **Sharma S**, Ramanathan RK, George DJ, Quinlan M, Kulkarni S, Homsy A, Scott JW, Infante JR (06/03/2013). *A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258)*. Poster session presented at American Society of Clinical Oncology, Chicago.
20. Carson SW, Grossmann K, Richards-Peterson LE, Ouellet D, Aktan G, Kendra K, LoRusso P, **Sharma S**, Middleton MR, Blackman SC, Suttle B (2014). *A Study of the Effect of Dabrafenib (D) as an Inducer of Cytochrome P450 (CYP) Using Warfarin (W) As a Probe*. Poster session presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta.
21. Suttle B, Grossmann K, Richards-Peterson L, Ouellet D, Aktan G, Gordon M, LoRusso P, Infante JR, **Sharma S**, Kendra K, Patel M, Pant S, Arkenau H, Middleton MR, Blackman SC, Carson SW (2014). *A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D)*. Poster session presented at Poster ASCPT, Atlanta.
22. Arkenau HT, Mateo J, Lemech CR, Infante JR, Burris HA, Bang YJ, Eder JP, Herbst RS, **Sharma S**, Chung HC, Decordova S, Swales KE, Garrett MD, Loftiss JI, Durante M, Russo MW, Suttle BB, Motwani M, Kumar R, De Bono JS (2014). *A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors*. Poster session presented at ASCO, Chicago.
23. Robinson Diamond J, Agarwal N, Bowles DW, Tat Lam E, Werner TL, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg GR, Sun YN, **Sharma S** (2014). *Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors*. Poster session presented at ASCO, Chicago.
24. Kim DW, Mehra R, Shao-Weng Tan D, Felipe E, Quan Man Chow L, Camidge DR, Vansteenkiste JF, **Sharma S**, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, Liu G, Santoro A, Geraldine M, Boral A, Yovine AJ, Tsang Shaw A (2014). *Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial*. Poster session presented at ASCO, Chicago.

25. Juric D, Soria JC, **Sharma S**, Banerji U, Azaro A, Desai J, Ringeisen FP, Kaag A, Radhakrishnan R, Hourcade-Potelleret F, Maacke H, Jahnert JR (2014). *A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors*. Poster session presented at ASCO, Chicago.
26. Reynolds KL, Juric D, Baselga J, Alsina M, Tabernero J, Bedard PL, Graham DM, Gonzalez-Angulo AM, Garrido-Laguna I, **Sharma S**, Lin CC, Cohen EEW, Lee SH, Zucchetto M, Tian X, Delgado L, Li J, Morozov A, Bang YJ (2014). *A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer*. Poster session presented at ASCO, Chicago.
27. Shao-Weng Tan D, Tsang Shaw A, Mehra R, Filip E, Quan Man Chow L, Camidge DR, Vansteenkiste JF, **Sharma S**, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler MH, Liu G, Santoro A, Geraldine M, Boral A, Yovine AJ, Kim DW (2014). *Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial*. Poster session presented at ASCO, Chicago.
28. Cleary JM, Jackson McRee A, O'Neil BH, **Sharma S**, Pearlberg J, Manoli S, Kubasek WL, Korn WM (2014). *A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers*. Poster session presented at ASCO, Chicago.
29. Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, **Sharma S**, O'Neil B, Wang B, Hui AM, Nemunaitis J (2015). *A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors*. Poster session presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts.
30. Harvey RD, Gore L, Wang D, Mita A, **Sharma S**, Nemunaitis J, Papadopoulos K, Pinchasik D, Ou Y, Demirhan E, Cutler RE, Tsimberidou AM (2016). *A Phase I Study to Assess Food Effect on Oprozomib in Patients with Advanced Malignancies*. Poster session presented at ASCPT, San Diego.
31. Tan DS, Kim DW, Thomas M, Pantano S, Wang Y, Szpakowski SL, Yovine AJ, Mehra R, Chow LQ, **Sharma S**, Solomon BJ, Filip E, Camidge DR, Vansteenkiste JF, Bitter H, Petruzzelli LM, Dugan MH, Shaw AT (2016). *Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1*. Poster session presented at ASCO, Chicago.
32. Naing A, Gelderblom H, Gainor JF, Forde PM, Butler M, Lin CC, **Sharma S**, Ochoa de Olza M, Schellens JHM, Soria JC, Taylor MH, Silva AP, Li Z, Bilic S, Cameron S, Infante JR (2016). *A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors*. Poster session presented at ASCO, Chicago.

ORAL PRESENTATIONS

Meeting Presentations (Not Published Abstracts and Not Unpublished Posters)

International

- | | |
|------|--|
| 2015 | International Symposium on Therapeutics Delivery
Development of Novel Beta Catenin Inhibitors for Treatment of Cancer
Seoul, Korea |
| 2016 | Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer. 2016 ASCO Oral Abstract
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke JJ, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Kurland J, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta AK, Segal NH |

National

- | | |
|------|--|
| 2013 | Discovery and Development of Specific LSD1 Inhibitors
EpiCongress-Fundamental Epigenetics |
|------|--|

2016 Boston, MA
CureSearch Catapult 2016
Accelerating a Novel LSD-1 Inhibitor to Pediatric Clinical Trials for Ewing
Sarcoma
Menlo Park, CA

Invited/Visiting Professor Presentations

National

2008 Contemporary Forums-Oncology: Clinical Issues and Trends
Addressing Colon Cancer Metastasis
Las Vegas, NV, USA

2010 Spring Update on Cancer Care jointly sponsored by Duke University School of
Medicine and Community Cancer Education, Inc.
Epigenetics and Its Role in Oncology
Las Vegas, NV, USA

2015 Cure and Prevention of BRCA-related Cancers: a Think Tank for Innovative
Strategies, Milestone Objectives and Research Priorities
Banbury Center, Cold Springs Harbor Laboratory, Cold Springs Harbor, NY, USA

2016 "Resistance and New Mechanisms of Action"
US Oncology Network 15th Annual Science Forum
Dallas, TX, USA

Local/Regional

2003 Evaluating, testing and Advancing Oncology Therapies.
Methodist Hospital, New York, NY

2003 Evaluating, testing and Advancing Oncology Therapies.
St. Lukes-Roosevelt Hospital, New York, NY

2003 Evaluating, testing and Advancing Oncology Therapies.
Newark Beth Isreal Hospital, Newark NJ

2004 Evaluating, testing and Advancing Oncology Therapies.
Temple University, Philadelphia, PA

2004 Evaluating, testing and Advancing Oncology Therapies.
New Mexico Society of Oncology, Albuquerque NM

2004 Evaluating, testing and Advancing Oncology Therapies.
Holy Cross Hospital, Ft. Lauderdale, FL

2004 Evaluating, testing and Advancing Oncology Therapies.
St. Vincent's Hospital, Brooklyn, NY

2004 Evaluating, testing and Advancing Oncology Therapies.
CCOP Symposium, Spartanburg, SC

2005 Evaluating, testing and Advancing Oncology Therapies.
Exl Pharma

2005 Evaluating, testing and Advancing Oncology Therapies.
Huntsman Cancer Institute, Salt Lake City, UT

2006 Evaluating, testing and Advancing Oncology Therapies.
MD Anderson Cancer Center, Houston, TX

2006 Evaluating, testing and Advancing Oncology Therapies.
Vanderbilt Cancer Center, Nashville, TN

2010 Huntsman-Intermountain Cancer Care Program (HICCP) Clinical Trial Webinar
Salt Lake City, UT, USA

2010 Cancer Center Annual Scientific Meeting
Bench to Bedside Approach to Cancer and Its Treatment

- Sharma, Sunil; Bearss, David
Huntsman Cancer Institute
Salt Lake City, UT, USA
- 2011 Cell Response and Regulation Program and Imaging, Diagnostics, and Therapeutics Program Mini-Symposium
Huntsman Cancer Institute
- 2011 Bearss D, Welm B, Andtbacka R, Bollag G, Prchal J, Fults D, Sharma S, Gillies, R
Howard Hughes Medical Institute (HHMI) Med into Grad Program
Translational Medicine Workshop: Clinical Development and Trials
Sharma, Sunil; Andtbacka, Robert
University of Utah
Salt Lake City, UT, USA
- 2011 Society of Utah Medical Oncologists 2011 Fall Meeting
Integrating Research into Community Oncology
Salt Lake City, UT, US
Sunil Sharma
- 2012 Entrepreneurial Faculty Scholars University of Utah Molecular Medicine Program (U2M2) and Center for Clinical and Translational Science (CCTS) 2nd Annual Translational Medicine Symposium
Salt Lake City, UT
Sharma, Sunil
- 2012 Huntsman-Intermountain Cancer Care Program (HICCP) 6th Annual Meeting
HICCP Clinical Trial Opportunities
Salt Lake City, UT
Sharma, Sunil and Akerley, Wallace
- 2012 Huntsman Cancer Institute and the Program in Personalized Health Care at University of Utah Symposium
Personalized Medicine: Research and Care in Oncology and Beyond
Salt Lake City, UT
- 2013 Entrepreneurial Faculty Scholars (EFS); University of Utah Molecular Medicine Program (U2M2); Center for Medical Innovation (CMI); and Center for Clinical and Translational Science (CCTS)
3rd Annual Translational Medicine Symposium: Bench to Bedside: The Rollercoaster Ride to the Clinic
Salt Lake City, UT
Sharma, Sunil
- 2015 2015 Genesis Biotechnology Group Distinguished Speaker Seminar Series: Discovery of Novel First-in-Class Orally Available Reversible LSD1 Inhibitors
Oncovada Cancer Research Center, Hamilton, NJ
- 2016 2016 ACS CAN Forum on Personalized Medicine
American Cancer Society Cancer Action Network, Salt Lake City, UT, USA

Peer-Reviewed Presentations

National

- 2011 Podium presentation, American Association for Cancer Research (AACR) Minisymposium #2788
Orlando, FL, USA
Design, optimization, and biological evaluation of potent irreversible inhibitors of BTK kinase
Bearss D, Sorna V, Warner S, Vankayalapati H, Bearss J, Sharma S

Grand Rounds Presentations

- 2012 Personalized Oncology: Impact of Emerging Genomic and Proteomic Information
on Clinical Care of Cancer Patients
University of Utah School of Medicine
Salt Lake City , UT
- 2015 Development of Novel Reversible Inhibitors of Lysine Specific Demethylase-1 as a
Therapeutic Strategy in Translocation Associated Sarcomas and Prostate Cancers
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, OK
- 2015 Development of Novel Reversible Inhibitors of Lysine Specific Demethylase-1 as a
Therapeutic Strategy in Translocation Associated Sarcomas and Prostate Cancers
Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute
New York, NY